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9III. REVIEW OF THE LITERATURE 
1. LIPOPROTEIN METABOLISM 
1.1 OVERVIEW 
Lipoproteins are soluble complexes of apolipoproteins and lipids that transport 
cholesterol and triglycerides in the circulation from one tissue site to another. 
Lipoproteins are synthesised from exogenous lipids by enterocytes in the intestine or then 
endogenously by hepatocytes in the liver, and can arise from the metabolic changes of 
circulating precursor lipoproteins. Most lipoproteins share a common spheroid structure 
consisting of a neutral lipid core of triacylglycerols and cholesteryl esters surrounded by a 
surface monolayer of phospholipids, unesterified cholesterol and apolipoproteins. The 
apolipoproteins solubilise the insoluble lipids and can act as cofactors for plasma 
enzymes and as ligands for cell surface receptors. Lipoproteins exist as a heterogeneous 
population of particles and the major classes are chylomicrons (CM), very low-density 
(VLDL), intermediate-density (IDL), low-density (LDL) and high-density (HDL) 
lipoproteins. Their relative contents of protein and lipid determines their hydrated 
density, size and mobility on agarose-gel electrophoresis and hence, their classification 
(Betteridge 1999). 
Lipoproteins are highly dynamic particles that are constantly modified in the 
circulation via a number of processes, such as enzymatic reactions affecting lipid 
components, spontaneous and facilitated lipid transfers, and from the exchange of soluble 
apolipoproteins between lipoprotein particles. The interaction of these processes largely 
specifies the delivery of lipids to different tissues. Most lipoproteins, with the exception 
of the largest, triglyceride-rich particles, can cross the vascular bed or endothelial cell 
layer by transcytosis and be internalised by cells for energy utilisation, membrane 
biogenesis or for the synthesis of various lipid-derived bioregulators like steroidogenic 
hormones and D-vitamins. They can also be assembled with cellular lipids of peripheral 
tissues and extracellular lipoprotein particles or apolipoproteins. After having crossed the 
endothelium, the route for lipoprotein recirculation is via the interstitial fluid of the main 
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trunk lymph ducts to the plasma for transport to the liver or kidneys for catabolism and 
excretion (Vance 2002). 
1.2. THE EXOGENOUS PATHWAY 
The exogenous pathway is defined as the transport and processing of dietary fats such as 
cholesterol, plant sterols and dietary fatty acids. Dietary fats must first be hydrolysed into 
monoacylglycerols and fatty acids for transport across the intestinal microvillus 
membrane to the enterocytes where they are then re-esterified for packaging into nascent 
CMs. Large amounts of triacylglycerols (TGs), together with a small amount of 
cholesteryl esters, are incorporated into the core of CMs which are composed of a 
phospholipid monolayer with apolipoprotein B-48. Newly formed CMs are then secreted 
into the mesenteric lymph and enter the circulation via the thoracic duct. Intestinal apoA-
I is also secreted and forms nascent HDL at the same time the CM reaches the circulation 
and undergoes TG lipolysis. A simultaneous movement of apoE and apoC proteins, from 
large spherical HDL reservoirs in the plasma, to the surface of the CM particle also 
occurs (Eisenberg 1984). The lipolytic enzyme, lipoprotein lipase (LPL), is 
predominantly bound to endothelial surfaces by heparin-like glycosaminoglycans and 
uses apoC-II as a cofactor for lipolysis (Goldberg et al. 1990). As the lipolytic reaction 
proceeds, apoC-II molecules are released, the TG core shrinks and the surface remnants 
are transferred to other lipoproteins, primarily to HDL. Free fatty acids (FFA) become 
bound to albumin as FFA/albumin complexes for transport to tissue sites of the body such 
as to muscle for energy use and to adipose tissue for storage. In cases of LPL deficiency, 
an alternative mechanism for FFA formation and uptake into adipose tissue is believed to 
be facilitated by endothelial lipase, a recently discovered phospholipase (Kratky et al. 
2005). The residual CM remnant particle, retaining most of its original cholesteryl ester 
and retinyl ester content, is finally endocytosed by the hepatic receptors; LDL-receptor 
(Herz et al. 1988) or low-density lipoprotein receptor-related protein (LRP), via apoE, for 
clearance by the liver (Russel et al. 1983). 
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1.3. THE ENDOGENOUS PATHWAY 
The endogenous pathway begins with the production and secretion of triglyceride-rich 
lipoproteins by the liver in the form of VLDL. In contrast to CMs, VLDL particles 
contain a triacylglycerol-rich core comprised of a substantial amount of hepatic 
cholesteryl esters, the surface phospholipid monolayer is enriched in 
phosphatidylethanolamine, and the apolipoprotein constituent is apoB-100. The 
enrichment of VLDL with apoE and additional apoC proteins takes place in the plasma 
compartment, similar to that of CMs. When VLDL particles reach the capillary bed, their 
TGs are hydrolysed by LPL and the surface lipid/apolipoprotein remnants are 
subsequently transferred to HDL by phospholipid transfer protein (PLTP). LPL-mediated 
hydrolysis of VLDL occurs less efficiently than that of chylomicrons and this is most 
likely the cause for the slower plasma clearance rate of VLDL (t1/2, days), as compared to 
chylomicrons (t1/2, minutes to a few hours) (Vance 2002). The prolonged residency of 
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VLDL particles in the plasma compartment generates short-lived IDL particles. 
Approximately 50 - 70 % of the IDL particles are further modified into LDL by the 
action of hepatic lipase (HL) and LPL (Demant et al. 1988), and the remaining IDL 
portion is rapidly cleared by the liver via high affinity binding to the LDL-R. The 
cholesterol-rich LDL particles are then transported from the circulation to the liver and to 
peripheral cells and are consequently taken up by receptor-mediated endocytosis (Brown 
et al. 1986). The LDL-R interacts with apoB-100 on the particle surface to facilitate 
internalisation; the receptor is released and recycles to the cell surface, and the LDL 
particle is degraded in lysosomes, ultimately providing the cell with an extracellular 
source of cholesterol. A coordinated utilisation of both the intra-and extra-cellular 
cholesterol pools must therefore take place under highly stringent sterol regulatory 
feedback mechanisms in order to prevent excessive amounts of cholesterol accumulating 
in the cell. 
1.4. REVERSE CHOLESTEROL TRANSPORT 
The transfer of cholesterol from peripheral tissues to the liver for recycling or degradation 
and excretion into bile is denoted as Reverse Cholesterol Transport (RCT) (Fielding et al. 
1995). This process is mediated by HDL particles that are formed when lipid-free apoA-I 
or lipid-poor preβ-HDL initiate the efflux of phospholipids and cholesterol from cell 
membranes via an interaction with the transmembrane ATP-binding cassette A1 
(ABCA1) (Santamarina-Fojo et al. 2000). Cholesterol acquired by these nascent discoidal 
HDL particles is then esterified by lecithin-cholesterol acyltransferase (LCAT) and the 
newly formed cholesteryl esters move to the core of the particle, thus producing spherical 
α-HDL. The steady gradient of free cholesterol is maintained by LCAT and is essential 
for enabling HDL to accept cholesterol from various donors (Fielding et al. 1995). HDL 
also acquires phospholipids from the lipolytic surface remnants of triglyceride-rich 
lipoproteins that are transferred by PLTP (Tall et al. 1985). Also, a reciprocal exchange 
of cholesteryl ester from HDL for TG from triglyceride-rich lipoproteins (CM and 
VLDL) occurs via the activity of cholesteryl ester transfer protein (CETP). This lipid 
exchange shifts the bulk of cholesteryl esters to apoB-100-containing lipoprotein particles 
for clearance by the liver and, at the same time, enriches HDL with TG. Triglyceride-
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enriched HDL consequently enhances HL-mediated lipolysis of the triglycerides and 
phospholipids thus assisting in the formation of smaller HDL3 particles and preβ-mobile 
HDL. Cholesteryl ester-enriched HDL particles deliver cholesteryl esters to the liver via a 
selective uptake process activated upon binding to the scavenger receptor-B1 (SR-B1) 
(Acton et al. 1996). Once cholesterol enters the liver it can then be re-assembled into new 
lipoproteins, incorporated into membranes, secreted as such into bile, or converted into 
oxysterols for bile acid synthesis. In order for the cycle of RCT to persist, new acceptors 
of cellular cholesterol (apoA-I, preβ-HDL) must be continuously synthesised or 
regenerated in reactions that are catalysed by PLTP, CETP and HL, acting in conjunction 
with ABC transporters to enhance cellular cholesterol efflux.
1.5. ATHEROSCLEROSIS
Atherosclerotic vascular disease develops from complex multifactorial processes that 
contribute to the deposition and accumulation of cholesterol in focal areas of the arterial 
wall. The pathobiology behind the progression of the disease involves a series of 
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oxidative and enzymatic modifications of subendothelial lipoproteins, endothelial 
alterations, multifaceted inflammatory responses such as T cell recruitment, cytokine 
secretion and monocyte chemotaxis, and most profoundly, the receptor-mediated cellular 
cholesterol uptake and accumulation in macrophages and also smooth muscle cells 
(SMC) (Glass et al. 2001; Lusis et al. 2004). These events take years to develop and 
result in the formation of foam cells that aggregate into complex lesions containing vast 
amounts of extracellular lipid and calcium which are covered by a fibrous cap. When 
these plaques become unstable and rupture, an occlusion of the arterial lumen by the 
contents of the plaque leads to haemorrhage, thrombosis and ultimately, to acute vascular 
events such as heart attack, stroke or sudden death. Indeed, cardiovascular disease (CVD) 
represents the most frequent cause of death in the industrialised world (Glass et al. 2001). 
With an aging population, genetic risk factors such as gender, diabetes and hypertension, 
along with the environmental influences of a ‘westernised’ high-fat diet, smoking and 
inactivity, to name but a few, the implications of this disease will severely impact many 
societies world-wide. This societal burden will undoubtedly magnify in spite of the 
valiant advances in plasma lipid-lowering therapies achieved thus far. 
2. HIGH DENSITY LIPOPROTEINS (HDL) 
2.1. ANTI-ATHEROGENIC PROPERTIES OF HDL 
The RCT pathway is believed to be one of the key mechanisms in the ability of HDL to 
provide a cardioprotective effect from the accumulation of non-hepatic peripheral cellular 
cholesterol. RCT entails the removal of cellular cholesterol by HDL at plasma 
membranes, and will therefore be described in more detail in section 2.4. Another 
mechanism by which HDL may impart its anti-atherogenic effects is through its ability to 
restore endothelial dysfunction by impacting on the bioavailability of nitric oxide (NO) of 
endothelial cells. During the early stages of atherosclerosis, a decreased bioavailability of 
NO, a potent vasodilator, as well as an increased affinity of the endothelial surface for 
leukocytes is observed (Voetsch et al. 2004). When HDL interacts with the surface of 
endothelial cells, it activates endothelial nitric oxide synthase (eNOS) through binding to 
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SR-B1 localised on caveolae (Yuhanna et al. 2001). HDL enhances eNOS activity by up-
regulating eNOS gene expression (Kuvin et al. 2002) and by increasing the 
phosphorylation pathway via activating the Akt kinase and mitogen-activated protein 
kinase (MAPK) (Mineo et al. 2003). This, in turn, causes a release of NO, which induces 
vasorelaxative effects and inhibits apoptosis. HDL also functions to attenuate the 
expression of vascular cell adhesion molecule (VCAM)-1, intracellular adhesion 
molecule (ICAM)-1, and E-selectin, all of which recruit leukocytes, especially 
monocytes, to the endothelial surface (Dimayuga et al. 1999). 
 The anti-atherogenic mechanism of HDL in inhibiting LDL lipid oxidation, 
especially via the 12-lipoxygenase-induced pathway, is believed to be crucial for 
preventing the scavenger receptor-mediated uptake of modified LDL particles into 
macrophage cells located within the subendothelial intima (Navab et al. 2004). The 
oxidation of phospholipids is largely generated by the lipoxygenase and myeloperoxidase 
pathways in the formation of cell-derived reactive oxygen species (ROS) (Vance 2002). 
These ROS oxidise lipoprotein phospholipids containing arachidonic acid, which in turn, 
makes the particles proinflammatory. The ability of HDL to inhibit oxidation and 
inflammation is by way of the high levels of antioxidants inherent in this lipoprotein, 
such as apoA-I, and the enzymes; paraoxonase (PON)-1 (Shih et al. 1998; Shih et al. 
2000) and platelet activating factor acetyl-hydrolase (PAF-AH) (Watson et al. 1995). 
These prevent oxidation reactions and catalyse the breakdown of oxidised phospholipids 
on the LDL particle. 
2.2. HDL STRUCTURE AND SUBPOPULATIONS 
Plasma HDL is a heterogeneous population of particles differing in size, density, surface 
charge, and in the apolipoprotein, enzyme and lipid composition (von Eckardstein et al. 
1994). The major apolipoproteins in HDL are apoA-I and apoA-II, as well as a minor 
portion of the metabolically important apoE, apoA-IV, apoD, apoJ, apoM and apoC (C-I, 
C-II and C-III) proteins (Xu et al. 1999; Bottcher et al. 2000). A subdivision into HDL1,
HDL2 and HDL3, by ultracentrifugal and gel-filtration separations, represents three major 
subclasses separated in decreasing order of particle size and increasing hydrated density. 
HDL1 is the least abundant and least dense subclass in plasma, whereas the HDL2 and 
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HDL3 subclasses are the most abundant and are therefore further subdivided into HDL2a,
HDL2b, HDL3a, HDL3b, and HDL3c (Anderson et al. 1977). The density range for HDL1 is 
from 1.050-1.090 g/ml; a region overlapping with LDL and HDL2. The density of HDL2
is from 1.063 to 1.125 g/ml, and for HDL3 the range spans from 1.125 to 1.21 g/ml. The 
approximate size diameter for HDL2 and HDL3 is 11 to 7 nm, respectively, and the core 
volume of HDL2 is 50 % larger than that of HDL3, containing 3 - 4 fold more cholesteryl 
ester and triglyceride molecules (Eisenberg 1984). Separation of HDL on the basis of 
surface charge by agarose gel electrophoresis and two-dimensional non-denaturing 
gradient gel electrophoresis has assisted in the separation of minor HDL subclasses from 
the most abundant α-HDL subclass (HDL2 and HDL3), and these are the preα-, preβ- and 
γ-migrating particles that are made of a single lipid bilayer, as determined by sectional 
electron microscopy (Hamilton et al. 1976). Furthermore, these particles are lipid-poor, 
composed of apoA-I (preα, preβ), apoA-IV (α, preβ) or apoE (γ-E) as the only protein 
constituents, and are good acceptors of cellular-derived cholesterol (von Eckardstein et al. 
1995; von Eckardstein et al. 1998). Likewise, preβ-HDL are present at higher levels in 
interstitial fluid than in plasma and are the main nascent forms of HDL that take up 
cholesterol from cells (preβ1-HDL), and undergo cholesterol esterification by LCAT (to 
form preβ2- and preβ3-HDL). Preβ1-HDL contains two molecules of apoA-I, which 
represents 90 % protein as particle mass, 7 % phospholipid (mostly phosphatidylcholine 
and sphingomyelin in equimolar ratio), 0.3 % esterified cholesterol and 1.8 % free 
cholesterol (Kunitake et al. 1985). Preβ2-HDL contains three apoA-I molecules, 
additional free cholesterol plus cholesteryl esters and an increased PC/SM ratio compared 
to that of preβ1 (Fielding et al. 1995). 
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2.3. HDL APOLIPOPROTEINS 
All of the apolipoproteins that associate with HDL, primarily apoA-I and apoA-II, along 
with the minor components mentioned in section 2.2, are defined as being exchangeable 
by their ability to transfer readily between lipoprotein particles, by being able to acquire 
lipids in the circulation and most importantly, by solubilising and transporting neutral 
lipids (cholesteryl ester and triacylglycerol) via a spontaneous binding to 
phospholipid/water interfaces (Alaupovic et al. 1972). Moreover, the exchangeable 
apolipoproteins are capable of altering their conformation according to changes in lipid 
content, compositions, and metabolic states of the lipoproteins, as well as to modulate 
enzymatic activities and to serve a role in receptor recognition (Jänis et al. 2005). 
 ApoA-I is the major protein constituent of HDL and comprises 70 % of its total 
protein mass. It is synthesised by the liver and the intestine as a pre-proprotein (267-aa), 
processed co-translationally to pro-apoA-I (249-aa) and secreted into the circulation (Law 
et al. 1984). A metalloenzyme rapidly cleaves the six amino acid-long propeptide from 
the amino terminus to form mature apoA-I (Edelstein et al. 1983). Mature apoA-I exists 
as a single polypeptide composed of 243 amino acids (molecular mass is 28 kDa). Exon 3 
encodes the N-terminal domain and the remaining region, which contains eight 22-mer 
and two 11-mer homologous repeats spanning residues 44-243, is encoded by exon 4 (Li 
et al. 1988). The amphipathic helical bundles contain a hydrophobic face that mediate 
55254133α1.125-1.2107-9HDL3
40335175α1.063-1.1259-12HDL2
22228426β1.019-1.06318-25LDL
191992923slow pre-β1.006-1.01925-35IDL
81871255pre-β0.95-1.00630-80VLDL
272386At origin0.9325-1200CM
ProteinaPLFCCETG
Electrophoretic 
Mobility
Density 
(g/ml)
Density 
(nm)Class
SURFACECORE
Chemical Composition
(% of dry mass)
CE, cholesteryl ester; FC, free cholesterol; PL, phospholipid; TG, triglyceride
aProtein does not include bound carbohydrate
(Adapted from: Lipoproteins in Health and Disease, 1999. Betteridge, Illingworth and Shepherd)
Table 1. Physical properties, lipid and apolipoprotein composition of human plasma lipoproteins
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binding to phospholipid surfaces so that the α-helical content increases upon lipid 
binding. ApoA-I for example, increases from a 50 % helical state when lipid-free to a 60-
85 % helical state when lipid bound and this occurs primarily at the C-terminal 187-243 
region (Davidson et al. 1996). When apoA-I is lipid-bound it adopts a ‘belt-like’ 
arrangement of a continuous series of α-helices that are aligned perpendicular to the 
phospholipid fatty acyl chains (Klon et al. 2002). In spherical HDL, apoA-I is most likely 
flexible with its conformation, being governed by the size and core lipid composition of 
the particles. The C-terminal end of apoA-I is also required for the activation of LCAT 
(Pyle et al. 1996). 
 ApoA-II is synthesised predominantly by the liver and is secreted into the plasma 
either as a propeptide, which is rapidly cleaved, or directly as mature apoA-II (Gordon et 
al. 1983). Human apoA-II is a disulfide-linked dimer composed of identical subunits and 
has a molecular mass of 17 kDa. ApoA-II normally represents 20 % of the total HDL 
protein content and is found in association with apoA-I in the plasma of normolipidemic 
subjects; however, apoA-I can also be found in particles not associated with apoA-II 
(Cheung et al. 1984).  
 The gene for apoE is polymorphic for three common alleles; ε2, ε3, and ε4, that 
code for three major isoforms which result in six common genotypes. Each isoform 
differs by cysteine and arginine at positions 112 and 158 such that apoE3, the most 
common isoform, contains cysteine residues at both sites, apoE4 contains only arginines 
and apoE2 contains both cysteine and arginine (Weisgraber et al. 1981). Human apoE is 
synthesised as a single polypeptide chain of 299 amino acids displaying similar primary 
and secondary structures to apoA-I, and having a molecular mass of 34 kDa. ApoE is a 
minor constituent of HDL, however, the profound effect of apoE on plasma HDL levels 
is demonstrated by an association of apoE4 with lower HDL-cholesterol concentrations 
and an increased risk for CVD (Kataoka et al. 1996; Wilson et al. 1996). 
ApoA-IV, a 46 kDa protein also associated with HDL, is able to mimic certain 
roles of apoA-I such as mediating cholesterol efflux and activating LCAT (Steinmetz et 
al. 1985; Steinmetz et al. 1990). Recently, apoM, a 26 kDa apolipoprotein expressed in 
the liver and kidneys, has been found to be associated with HDL particles and to be a 
modulating factor for the formation of preβ-HDL. In apoM-deficient mice, a complete 
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absence of preβ-HDL is observed, together with a reduced capacity for cholesterol efflux 
from macrophage cells to apoM-deficient HDL, compared with normal HDL (Wolfrum et 
al. 2005). Finally, the apoC proteins (apoC-I; 6.6 kDa, apoC-II; 8.9 kDa and apoC-III; 8.8 
kDa) of HDL display either inhibitory or stimulatory effects on various enzymes and lipid 
transfer proteins. For instance, apoC-II activates LPL whereas apoC-III inhibits it, and the 
apoC-I protein has been shown to inhibit CETP activity (Gautier et al. 2000; Shachter 
2001). 
2.4. FORMATION OF HDL 
The formation of HDL begins with the synthesis of monomolecular lipid-poor apoA-I 
displaying preβ mobility in agarose gel electrophoresis and containing only a small 
amount of phospholipid. Lipid-poor apoA-I in plasma is derived from; synthesis in the 
liver and the intestine (Eisenberg 1984), release from triglyceride-rich lipoproteins during 
LPL-mediated lipolysis (Schaefer et al. 1982), and during the remodelling of mature, 
spherical HDL particles in plasma (Rye et al. 1999). For the formation of discoidal preβ-
HDL, lipid-poor apoA-I must initially accept phospholipid and cholesterol from cell 
membranes provided by ABCA1. The ABCA1 transporter was originally identified as 
one of the key regulators of cellular cholesterol efflux after the mutated form of the gene 
was revealed in human fibroblast cells of Tangier patients (Bodzioch et al. 1999; Brooks-
Wilson et al. 1999). These patients display a deficiency of plasma HDL due to rapid 
degradation of lipid-poor apoA-I, as well as an accumulation of macrophage foam cells in 
various tissues and moderately accelerated atherosclerosis. The function of ABCA1 is to 
increase the availability of cholesterol and phospholipid at the cell surface with which 
apoA-I directly interacts (Chambenoit et al. 2001). Binding of apoA-I either occurs on the 
plasma membrane at sites interrupted by ABCA1 or otherwise directly to the two large 
extracellular domains of the transporter (Wang et al. 2000). Moreover, ABCA1 is not 
restricted to the cell surface as it shuttles between early and late endosomes and the 
plasma membrane, recycling apoA-I and transporting cholesterol to the cell surface for 
export (Neufeld et al. 2001). Early hepatic lipidation events occur within endocytic 
compartments during recycling, or as has recently been reported, within the secretory 
pathway upon apoA-I synthesis (Chisholm et al. 2002; Zheng et al. 2005). As apoA-I 
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acquires enough free cholesterol and phospholipid to remodel into a discoidal structure, 
further growth and maturation is dependent on the enzymatic activity of LCAT, which 
consumes unesterified cholesterol and phosphatidylcholine to produce insoluble 
cholesteryl esters (Nakamura et al. 2004). Cholesteryl esters move to the core, thus 
forming a spherical particle and a concentration gradient that enables more free 
cholesterol and phospholipids to move from the cell and lipoprotein surfaces to the 
growing HDL particle. 
Two other members of the ABC transporter family, ABCG1 and ABCG4, have 
recently been shown to promote net cholesterol efflux to HDL particles, primarily to 
HDL2 and HDL3 (Wang et al. 2004). This is in contrast to ABCA1 which mediates efflux 
mainly to lipid-poor apolipoproteins, such as to apoA-I, and not to HDL particles that 
constitute the bulk of plasma HDL. As ABCG1 is highly expressed in macrophage foam 
cells it may explain the inverse relationship between large-sized HDL2 and 
atherosclerosis risk (Lorkowski et al. 2001). 
2.5. HDL CATABOLISM 
Clearance of plasma HDL by the liver is an essential process for the catabolism of 
cholesterol into bile acids for excretion. The hepatic uptake of cholesteryl esters in HDL 
is facilitated by SR-B1, a multi-ligand cell surface transmembrane protein, that may be 
responsible for the selective sorting of cholesterol to the bile canaliculus (Acton et al. 
1996). The SR-B1 pathway is a high-capacity system in which cells selectively 
internalise cholesteryl esters, but not the apolipoprotein component of the HDL particle 
(Ji et al. 1997). Another pathway independent of SR-B1 that has been proposed is the 
catabolic pathway for HDL protein through the high-affinity binding of the particle to a 
novel receptor, the β-chain of ATP synthase, a protein complex of the mitochondrial 
inner membrane (Martinez et al. 2003). Ectopic expression of the β-chain of ATP 
synthase has been shown to facilitate endocytosis of holo-HDL particles by a mechanism 
that depends on the generation of adenosine diphosphate (Martinez et al. 2003). However, 
the extent to which this receptor plays a role in HDL metabolism in vivo remains to be 
shown. Finally, hepatic uptake of HDL-derived cholesteryl esters also occurs via the 
action of CETP which transfers cholesteryl esters from HDL particles to apoB-100-
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containing lipoproteins that are then internalised by the liver through LDL-receptor (R)-
mediated endocytosis (Tall 1993). 
In addition to the catabolism of HDL and its components in the liver, degradation 
of HDL also occurs in the kidneys. The mechanism for HDL binding and endocytosis is 
through the cubilin-megalin pathway which involves the cubilin receptor, a peripheral 
membrane protein that is assembled with the amnionless transmembrane protein, and its 
co-receptor megalin (Christensen et al. 2002; Strope et al. 2004). The cubilin/amnionless 
complex is expressed along the apical surfaces of kidney proximal tubule cells and clears 
lipid-poor apoA-I, as well as lipid-depleted HDL3 particles via binding to its ligand, 
apoA-I, for internalisation and lysosomal degradation (Hammad et al. 1999; Kozyraki et 
al. 1999; Fyfe et al. 2004). 
2.6. LIPID TRANSFER PROTEINS 
In human plasma, the transfer of lipid species between lipoprotein particles occurs via the 
action of two distinct lipid transfer proteins; cholesteryl ester transfer protein (CETP) and 
phospholipid transfer protein (PLTP). CETP is a hydrophobic glycoprotein that is 
secreted primarily by the liver and circulates in plasma, bound mainly to HDL (Tall et al. 
1983). The function of CETP is to promote the redistribution of cholesteryl esters from 
HDL to triglyceride-rich lipoproteins and of triglycerides from triglyceride-rich 
lipoproteins to LDL and HDL. PLTP mediates the transfer of phospholipids from 
triglyceride-rich lipoproteins to HDL as well as the remodelling of HDL so that, together 
with CETP, it plays an important role in the pathway of RCT by modifying the metabolic 
properties and size distribution of HDL (Huuskonen et al. 2000). 
CETP was originally designated Lipid Transfer Protein-I (LTP-I) and PLTP was 
designated LTP-II upon isolation and purification of these two proteins in human plasma 
(Tollefson et al. 1988). When human CETP and PLTP were subsequently cloned, 
sequence analysis revealed a 21.7 % amino acid identity between the two proteins. In 
addition, CETP and PLTP belong to the same gene family; the lipid 
transfer/lipopolysaccharide binding protein family (Day et al. 1994). The other family 
members include bactericidal/permeability-increasing protein (BPI) and 
lipopolysaccharide-binding protein (LBP). BPI and LBP mediate anti-bacterial and pro-
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inflammatory activities via binding to lipopolysaccharide (LPS) on the outer membrane 
of Gram-negative bacteria (Gray et al. 1989; Schumann et al. 1990). In addition to 
humans, homologous CETP and PLTP genes have been found in other mammalian 
species. PLTP activity has been detected in all species studied thus far but, in contrast, 
substantial CETP activity is found only in man, rabbit, chicken and trout (Guyard-
Dangremont et al. 1998). Importantly, CETP is not present in the mouse, the most 
commonly used experimental animal model of atherosclerosis (Breslow 1996). On the 
basis of the available crystal structure of the closely related BPI, computational models of 
CETP and PLTP have since been constructed (Bruce et al. 1998; Huuskonen et al. 1999). 
These models from both proteins predict an elongated, boomerang-like structure 
containing two highly conserved, hydrophobic lipid binding pockets. The amino terminal 
domains in CETP and PLTP are highly homologous whereas the carboxyl terminal 
domains vary in hydrophobicity and hence, functional specificity. 
The possibility that CETP and PLTP might act as independent risk factors in the 
development of atherosclerosis has raised the question of whether they are protective 
against or detrimental to the disease progression. As PLTP will be discussed in detail in 
the following chapter, only CETP and its role in atherogenesis will be outlined below. 
The pro-atherogenic nature of CETP and the possibility to inhibit its activity to 
favour an anti-atherogenic lipoprotein profile was raised over a decade ago (Brown et al. 
1989). The potential for CETP as a pro-atherogenic factor relates to its ability to transfer 
cholesteryl esters from anti-atherogenic HDL particles to pro-atherogenic VLDL and 
LDL fractions. CETP also functions to mediate the selective uptake of cholesteryl esters 
by human adipose tissue (Benoist et al. 1997). Adipocytes synthesise and secrete CETP, 
which is immunoreactive on the plasma membrane, and selectively acquire cholesteryl 
esters from HDL. CETP also facilitates the uptake of HDL-cholesteryl esters (CE) by 
hepatic cells expressing SR-B1 (Collet et al. 1999). The effect of CETP activity on the 
development of atherosclerosis, however, is not straightforward. For example, the 
development of atherosclerosis in CETP-transgenic mice depends both on diet and on 
other genes that affect lipoprotein metabolism. When the human CETP gene is expressed 
in mice, a species naturally deficient in CETP, a dose-related reduction in HDL 
cholesterol levels and a small increase in VLDL and LDL cholesterol occurs (Agellon et 
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al. 1991). More strikingly, in transgenic mice expressing the simian CETP gene driven by 
the mouse metallothionein promoter, the development of atherosclerosis occurs rapidly 
and lesion morphology is severe (Marotti et al. 1993). Conversely, circumstances in 
which CETP gene expression in mice have been found to be anti-atherogenic have also 
been reported. This includes mice that, in addition to CETP, have been engineered to over 
express the human apoC-III gene, the human LCAT gene as well as in mice that have 
hypertriglyceridemia (Hayek et al. 1995; Berard et al. 1997; Kako et al. 2002). Such 
conflicting reports illustrate the complexity and inconsistencies arising from studies in 
CETP transgenic mice. Rabbits on the other hand, are highly susceptible to diet-induced 
atherosclerosis and display naturally high levels of CETP (Quinet et al. 1990). When 
rabbits are injected with antisense oligonucleotides against CETP to inhibit expression, 
atherosclerosis is substantially reduced and HDL cholesterol levels are elevated (Sugano 
et al. 1998). Small CETP inhibitors have recently been shown to not only increase HDL 
cholesterol levels, but also to affect the size distribution of HDL subpopulations and the 
apolipoprotein and enzyme composition in rabbits (Okamoto et al. 2000; Rittershaus et 
al. 2000; Brousseau et al. 2004; Clark et al. 2004; Zhang et al. 2004). 
CETP deficiency in humans has been attributed to several missense, nonsense and 
splicing mutations in the CETP gene. This invariably results in elevated levels of HDL 
cholesterol, apoA-I, apoA-II and apoE as well as a substantial reduction in the 
concentration of LDL cholesterol and apoB (Inazu et al. 1990). Therefore, despite the 
inconsistent results obtained from transgenic mice, the atherogenic effects of CETP 
expression in rabbits and the anti-atherogenic profile of CETP deficiency in humans 
strongly support a therapeutic potential for CETP inhibition (Clark et al. 2004; Brousseau 
et al. 2005). 
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3. PHOSPHOLIPID TRANSFER PROTEIN (PLTP) 
3.1. CHARACTERISTICS OF PLTP 
The human PLTP gene has been mapped to chromosome 20q12-q13.1, which is in close 
proximity to the genes for LBP and BPI located on 20q11.23-q12 (Gray et al. 1993; 
Whitmore et al. 1995). The intron positioning as well as the exon size and distribution for 
PLTP, BPI and LBP are almost identical and with the structural organisation of the entire 
LPS-binding/lipid transfer protein family members being highly conserved, the presence 
of a common ancestral gene is evident (Hubacek et al. 1997; Kirschning et al. 1997). The 
PLTP gene is approximately 13.3 kilobases (kb) in length and comprises 16 exons that 
range in size from 43 base pairs (bp) (exon 13) to 304 bp (exon 16), along with 15 
intervening introns (Tu et al. 1995). The first exon of the PLTP gene contains the 5’-
untranslated region with an interruption by intron 1 occurring 11 bp upstream of the 
translation initiation site, a feature characteristic of most apolipoprotein genes (Li et al. 
1988). The second exon of the PLTP gene contains the entire signal peptide, which is 
cleaved from the protein upon secretion, and also contains 16 amino acids of the mature 
protein. Exons 3 to 15 encode mainly the mature protein and exon 12 encodes a segment 
of 21 amino acids (residues 372-392) that consists of seven basic amino acids that form a 
heparin binding site on PLTP. Exon 16 contains partly coding as well as the entire 3’-
untranslated region (Tu et al. 1995). 
A gene named human protective protein has been found to partially overlap by 58 
nucleotides at the 3’-untranslated region with the PLTP gene (Shimmoto et al. 1996). 
This overlap results in the convergent transcription of both genes from opposite DNA 
strands and is found to exist also in the mouse genome. PLTP and human protective 
protein mRNA expression patterns do not, however, coincide, nor are they mutually 
affected by individual gene expression levels. This indicates that both genes, despite their 
close proximity, are not cooperatively regulated (Jiang et al. 1996). The mouse PLTP 
gene which is localised to chromosome 2, corresponding to human chromosome 20, 
exhibits intron-exon junctions that are highly conserved with the human PLTP gene and 
shares an 81.1 % nucleotide sequence identity in the promoter region (LeBoeuf et al. 
1996; Tu et al. 1997). Considering that the human PLTP promoter region responsible for 
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transcription has been determined to be between -230 and -72 relative to the transcription 
initiation site, contains a TATA box, a high GC region and several consensus sequences 
for the potential binding of transcription factors such as Sp1, AP-2, AP-3, C/EBP, NF-
kB, it is reasonable to assume that the mouse PLTP promoter is located at the same 
region and is subject to similar transcriptional regulation mechanisms (Tu et al. 1995; Tu 
et al. 1997). 
PLTP complementary DNA (cDNA) is 1750 bp in length and encodes a 17 amino 
acid hydrophobic signal peptide and a 476 amino acid mature protein (Day et al. 1994). 
The messenger RNA (mRNA) of PLTP is ubiquitously expressed and the presence of a 
single transcript of 1.8 kb of mRNA occurs at the highest levels in the ovary, thymus and 
placenta, and at moderate levels in the pancreas, small intestine, testes, lung, and prostate. 
Relatively low levels of the transcript have been detected in the kidney, liver, and spleen, 
as well as very low levels in the heart, colon, skeletal muscle, leukocytes and brain (Day 
et al. 1994; Albers et al. 1995). This indicates that PLTP gene expression has a tissue-
specific regulation and this appears to differ between human and mouse tissues (Albers et 
al. 1995). Although moderate levels of PLTP mRNA have been found in the liver, the 
relatively large mass of this organ may still make it a major contributor to plasma PLTP 
levels. 
The mature PLTP protein has a predicted molecular mass of 55 kDa, yet the 
observed 81 kDa by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) of purified plasma PLTP under reducing conditions is due to extensive 
glycosylation (Day et al. 1994; Huuskonen et al. 1998). For example, the major secreted 
forms of PLTP carry complex N-glycans at six potential N-glycosylation sites 
(Huuskonen et al. 1998). When PLTP is expressed in a baculovirus/insect-cell system, 
which is capable of performing only high-mannose type glycosylation, efficient secretion 
and full activity of the protein is still observed (Huuskonen et al. 1998b). PLTP also has 
numerous potential O-glycosylation sites and this may account for the increased mass 
estimation by SDS-PAGE.  PLTP contains four cysteine residues with the potential to 
form two intra-chain disulfide bonds, whereby the bridge that is formed between cysteine 
residues 146 and 185 is found to be important for the structural integrity of the protein 
(Huuskonen et al. 1999). According to homology modelling, PLTP displays a two-
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domain architecture composed of two symmetrical barrels with hydrophobic pockets. 
Site-directed mutagenesis of conserved amino acid residues has revealed that the N-
terminal pocket is critical for PLTP transfer activity and that the C-terminal pocket is 
required for HDL binding (Huuskonen et al. 1999). The final 30 C-terminal amino acid 
residues are not required for secretion or activity (Huuskonen et al. 1999). Based on 
secondary structure predictions, PLTP is also thought to contain two potential 
transmembrane regions spanning from residues 169 through 181, and residues 288 
through to 304 (Albers et al. 1996b). However, there is no evidence that these would 
anchor PLTP integrally to membranes. Finally, PLTP displays a high content of 
hydrophobic residues that are scattered throughout the polypeptide representing more 
than 40 % of the total amino acids. 
3.2. FUNCTIONS OF PLTP 
3.2.1. PHOSPHOLIPID TRANSFER ACTIVITY 
PLTP transfers phospholipids from triglyceride-rich lipoproteins to HDL during lipolysis 
(Tall et al. 1985). This function was discovered via an in vitro method in which 
Figure 3. Molecular model of phospholipid transfer protein
(Huuskonen et al. 1999. J Lipid Res 40:1123-30)
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phospholipid vesicles were incubated with HDL or plasma (Tall et al. 1981). By using 
this method it was discovered that the rate of transfer of radiolabelled 
phosphatidylcholine from unilamellar egg phosphatidylcholine vesicles to HDL was 
sufficiently enhanced by the activity of LTP-II, nowadays termed PLTP (Tall et al. 1985). 
The phospholipid substrate specificity of plasma PLTP has since been determined from 
the acyl chain length and polar head groups of different pyrene-labelled phospholipids 
(Huuskonen et al. 1996; Rao et al. 1997). These studies demonstrate that PLTP is capable 
of transferring all common phospholipid classes non-specifically, except for 
phosphatidylethanolamine which is transferred more slowly, and this transfer is 
unaffected by the acyl chain length (from 6-12 carbons) or the acyl chain position at sn-1 
or sn-2. As no PLTP-phospholipid intermediates have been detected, it appears unlikely 
that PLTP would form a tight complex with its lipid substrate. Accordingly, instead of 
being a true lipid carrier it is more probable that PLTP forms a ternary complex between 
donor and acceptor particles to facilitate the transfer of phospholipids. The exact 
mechanism behind PLTP-facilitated phospholipid transfer, which is responsible for 
approximately half of the overall exchange activity between lipoproteins, the other half 
being mediated by CETP, has not been fully resolved (Brown et al. 1990). However, the 
physiological importance of PLTP in vivo is evident in PLTP-deficient mice, which show 
a total absence of transfer of phospholipids from VLDL to HDL in plasma, along with 
markedly decreased HDL levels and a subsequent accumulation of surface remnants in 
apoA-IV-rich lamellar lipoproteins (Jiang et al. 1999; Qin et al. 2000). 
 The non-specificity of PLTP-mediated phospholipid transfer is also extended to 
its ability to transfer diacylglycerol (Rao et al. 1997). Diacylglycerols are not only 
released by LPL in the capillary endothelium and during lipolysis in adipose tissue, but 
diacylglycerol is also transported in HDL particles (Vieu et al. 1996). Furthermore, PLTP 
enhances the transfer of other lipophilic substances such as α-tocopherol (vitamin E) 
(Kostner et al. 1995), LPS (Hailman et al. 1996; Levels et al. 2005), and cholesterol 
between cells and lipoproteins (Nishida et al. 1997). The importance of α-tocopherol as 
an anti-oxidant of plasma lipoproteins and cell membranes is its role in inhibiting LDL 
oxidation and the subsequent uptake of these particles by vascular cells. Originating from 
the intestine, α-tocopherol is firstly incorporated into chylomicrons, transported to the 
28
liver and then packaged into nascent VLDL particles for release into the circulation. 
PLTP removes α-tocopherol from atherogenic lipoproteins in vitro and PLTP over-
expression reverses the beneficial phenotype of the decreased susceptibility to 
atherosclerosis observed in PLTP-knockout (KO) mice (Jiang et al. 2002; Yang et al. 
2003). Hence, the deleterious loss of α-tocopherol from apoB-containing lipoproteins can 
be verified by the concomitant increase in the oxidizability of these lipoproteins (Yang et 
al. 2003). On the other hand, PLTP deficiency in the brain, an organ displaying a rich 
source of α-tocopherol in the body, results in decreased levels of α-tocopherol and an 
increase in oxidative brain injury that subsequently leads to neurological dysfunctions 
(Desrumaux et al. 2005). Such findings prompted the authors of this study to suggest a 
novel function for PLTP as a local transporter of α-tocopherol, offering a putative route 
of transfer of α-tocopherol across the blood-brain barrier. 
3.2.2. HDL CONVERSION 
In addition to transferring lipophilic substances between lipoproteins, PLTP also 
functions to maintain the heterogeneity of plasma HDL via a conversion process that 
modifies HDL3 into a population of enlarged HDL2 particles, together with a concomitant 
release of apoA-I molecules termed small dense preβ1-HDL (Jauhiainen et al. 1993; Tu et 
al. 1993). This process involves particle fusion rather than a net lipid transfer or particle 
aggregation for the enlargement of HDL and relies on the interaction of PLTP with apoA-
I on HDL (Lusa et al. 1996; Korhonen et al. 1998; Huuskonen et al. 2000c). The fusion of 
unstable particles is suggested to be a response to the phospholipid transfer process that 
increases the surface pressure of HDL which releases apoA-I from the surface (Lusa et al. 
1996). HDL conversion is a process dependent on both PLTP concentration and time and 
proceeds as a continuum of intermediate particle formation with the transfer of 
phospholipids preceding the change in particle size (Rao et al. 1997). In addition to 
human PLTP, mouse recombinant PLTP also facilitates HDL conversion as well as pig 
PLTP which can convert not only homogeneous pig HDL but also human HDL3 into 
larger and smaller particles (Albers et al. 1995; Pussinen et al. 1995). With a continued 
interest in HDL remodelling by PLTP, further studies have shown that an enrichment of 
HDL with triglycerides enhances the rate of conversion, an interesting observation 
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considering that hypertriglyceridemic patients contain higher amounts of small HDL than 
normolipidemic controls due to accelerated remodelling (Murakami et al. 1995; Rye et al. 
1998). The process of remodelling is believed to be most important for the formation of 
small preβ1-HDL conversion products as they are rich in apoA-I, devoid of triglycerides 
and have an approximate equimolar PC/SM ratio; the preferred lipoprotein species that 
serves as the initial acceptor of cellular unesterified cholesterol (Sviridov et al. 2002). 
Furthermore, HDL2 can serve as a substrate for PLTP in generating preβ-HDL (Marques-
Vidal et al. 1997). 
3.2.3. CELLULAR CHOLESTEROL EFFLUX 
In addition to PLTP’s role in lipoprotein metabolism in the plasma compartment, 
increasing evidence points to a function for PLTP in hepatic and extra-hepatic tissues. A 
positive correlation between human serum PLTP activity and cellular cholesterol efflux 
was initially demonstrated in Fu5AH rat hepatoma cells by the ability of PLTP to 
augment the removal of cellular phospholipids and cholesterol into HDL (Syvanne et al. 
1996). Furthermore, exposure of cholesterol-enriched human skin fibroblasts to PLTP 
enhanced cholesterol efflux to HDL, but not to albumin and this did not occur in 
fibroblasts from Tangier patients who lack the ABCA1 transporter (Wolfbauer et al. 
1999). It was later suggested that the enhancement of lipid efflux by PLTP occurs via 
interplay with ABCA1. In the presence of HDL acceptor particles, PLTP efficiently 
stimulates phospholipid and cholesterol efflux and stabilises ABCA1 from calpain-
mediated degradation and, together with apoA-I, binds to the same or closely related sites 
on ABCA1 at the cell surface (Oram et al. 2003). In the plasma of ABCA1-KO mice, 
PLTP and LCAT activities are decreased by more than 80 %, suggesting that the 
maturation of HDL is substantially affected, and thereby provides a plausible explanation 
for the low HDL levels observed when ABCA1 is absent (Francone et al. 2003). It may 
also be possible that PLTP promotes cellular lipid efflux via an indirect mechanism, such 
as by increasing the concentration of plasma preβ1-HDL (von Eckardstein et al. 1996). 
For example, plasma from huPLTP transgenic mice is more efficient at preventing the 
acetylated LDL-induced accumulation of intracellular cholesterol in cultured 
macrophages so that the increased plasma concentration of preβ1-HDL by elevated PLTP 
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may be contributing more to the RCT pathway (van Haperen et al. 2000). Additionally, 
chymase, a neutral protease secreted by mast cells in human atherosclerotic lesions, can 
proteolytically degrade PLTP and so irreversibly inhibit the PLTP-dependent formation 
of preβ1-HDL with ensuing impairment of cholesterol efflux from macrophage cells (Lee 
et al. 2003). Alternatively, PLTP could function as an atherogenic molecule by mediating 
cellular lipid retention and this may be explained by the high PLTP mRNA expression 
levels in macrophage foam cells of atherosclerotic plaques which correlate with increased 
cellular cholesterol levels. For instance, when macrophage cells are loaded with 
cholesterol in vitro a 2- to 3-fold increase in PLTP steady-state mRNA levels, protein 
expression and activity is observed (O'Brien et al. 2003). 
3.3. REGULATION OF PLTP GENE EXPRESSION 
Even though the PLTP gene promoter was found not to display homology to steroid 
hormone response elements, it does contain response elements to non-steroidal receptors 
such as farnesoid X-activated receptor (FXR), peroxisome proliferator-activated receptor 
α (PPARα), and the liver X-activated receptor (LXR) (Tu et al. 2001; Laffitte et al. 
2003). These nuclear receptors bind DNA as heterodimers with their obligate partner, 
retinoid X receptor (RXR) (Chawla et al. 2001). Transcriptional regulation of many genes 
that are involved in bile acid and cholesterol metabolism occurs via the pivotal role of 
various members of the orphan nuclear hormone receptor superfamily. As PLTP is one 
such target gene of the nuclear receptors it contains, in addition to several transcriptional 
binding sites (sterol regulatory element-binding protein [SREBP], CCAT/enhancer-
binding protein [C/EBP]), several response elements in its promoter region such as one 
for FXR (Tu et al. 1999). Within the PLTP promoter region is an inverted repeat-1 
response element (IR-1) to which FXR binds once it has formed a heterodimer with 
RXRα. Chenodeoxycholic acid (CDCA), a bile acid and potent activator of FXR, is 
capable of inducing human PLTP promoter expression 8-10 fold in the presence of FXR-
RXRα (Urizar et al. 2000). CDCA is also capable of inducing mouse PLTP gene 
expression (Tu et al. 2001), and the effect is lost in FXR-KO animals (Kast et al. 2001). It 
is proposed that when bile acids increase due to a higher cholesterol concentration, 
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elevated PLTP gene expression would subsequently raise or otherwise maintain HDL 
levels (Urizar et al. 2000). 
In addition to FXR response elements, the PLTP promoter region also contains 
PPARα-responsive element-like sequences, to which PPARs bind after heterodimerising 
with RXRα upon fatty acid or fibrate-induced activation. Fibrates constitute a class of 
normolipidemic drugs that efficiently decrease triglycerides and increase HDL plasma 
levels in humans (Brown 1987). Fenofibrate profoundly affects the promoter activity of 
the human PLTP gene by lowering its expression (Tu et al. 1999). Furthermore, as C/EBP 
and PPARα share the same binding region on the PLTP gene, C/EBP may compete for 
PPARα binding, subsequently modifying gene promoter function in response to fibrate. It 
has been documented that the ratio of PPARα and C/EBP proteins within cells seems to 
dictate PLTP gene transcription in response to fibrate (Tu et al. 1999). Interestingly, 
when fenofibrate is applied to the mouse, PLTP gene expression significantly increases, 
the opposite effect being observed for PLTP in humans (Tu et al. 2001). This indicates 
that, despite the mechanisms for basic transcription of the PLTP gene in human and 
mouse being highly conserved, the regulatory pathways in response to environmental 
stimuli for PLTP gene expression appears to be species-specific. 
LXRs, also belonging to the orphan nuclear receptor superfamily, act as master 
transcription factors for the regulation of cholesterol absorption in the intestine, 
cholesterol catabolism in the liver, and cholesterol efflux from peripheral tissues (Schultz 
et al. 2000). The LXR subfamily of nuclear receptors are bound and transcriptionally 
activated by oxidised forms of cholesterol (oxysterols) (Lehmann et al. 1997), and the 
LXR target genes include; apoE (Laffitte et al. 2001), LPL (Zhang et al. 2001), ABCG1 
(Kennedy et al. 2001), ABCG5 and ABCG8 (Repa et al. 2002), FAS (Joseph et al. 2002), 
ABCA1, CETP, rodent Cyp7A and SREBP1c (Edwards et al. 2002). PLTP is also a 
direct target gene for LXR as the PLTP promoter region contains a high-affinity LXR 
response element that is bound by LXR/RXR heterodimers (Laffitte et al. 2003). 
LXR/RXR heterodimers are known to bind to direct repeats of a hexanucleotide repeat 
spaced by 4 bp (DR-4). The functional LXR-response elements in the PLTP gene that are 
necessary for maximal induction correspond to DR-4A and DR-4B sequences and show 
significant similarity to other known LXR-response elements (Laffitte et al. 2003). 
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Oxysterols and synthetic LXR ligands strongly regulate the expression of murine and 
human PLTP genes in the liver and in macrophage cells in an LXR-dependent manner 
(Cao et al. 2002; Mak et al. 2002; Laffitte et al. 2003). When specific LXR agonists are 
administered to mice, hepatic PLTP mRNA and plasma PLTP activity increases. This 
occurs alongside HDL cholesterol and phospholipid elevation, which generates enlarged 
HDL particles that are enriched in cholesterol, apoA-I, apoE and phospholipid (Cao et al. 
2002). Such HDL enlargement may also involve the induction of ABCA1 and apoE; the 
genes that are also involved in HDL metabolism and regulated by LXRs. Short term 
administration of synthetic LXR ligands in animals has been shown to induce ABCA1 
and increase plasma HDL cholesterol and phospholipid levels, yet plasma triglycerides 
also rise (Schultz et al. 2000; Joseph et al. 2002). In order to overcome the 
hypertriglyceridemia mediated by LXR activation but without losing the advantageous 
effects of LXR-mediated HDL enlargement and hepatic PLTP mRNA induction, a 
simultaneous activation of LXRs and PPARα by synthetic ligands has been shown to 
dissipate triglycerides in the liver and plasma without hindering the favourable formation 
of enlarged HDL and increased PLTP (Beyer et al. 2004). It is interesting that PLTP is 
also highly expressed in macrophage cells within atherosclerotic lesions, inducible by 
LXR, especially considering that the pharmacological activation of LXR has been shown 
to inhibit the formation of atherosclerotic lesions in mouse models (Joseph et al. 2002b). 
With FXR also regulating PLTP in the liver but not being expressed in macrophage cells, 
it is clear that PLTP can be regulated independently by either receptor and that LXR 
appears to play a crucial role in PLTP expression in macrophage foam cells. 
3.4. PLTP IN HUMAN PLASMA AND TISSUES 
Human genetic PLTP deficiency has not been unequivocally described thus far, apart 
from one case reported in an abstract form (Mallow et al. 1994), and the effects of PLTP 
polymorphisms on lipoprotein metabolism have not as yet been clearly delineated. 
Plasma PLTP activity levels do not significantly differ between males and females and 
the genetic variation of the PLTP gene within a normal Finnish population, identified by 
six intragenic and two neutral polymorphisms, showed no significant associations with 
plasma PLTP activity (Tahvanainen et al. 1999). Plasma PLTP activity increases with age 
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and correlates positively with body mass index, serum cholesterol and triglycerides 
(Tahvanainen et al. 1999). In premenopausal women, PLTP activity correlates positively 
with IDL and buoyant LDL particles, but not with dense LDL fractions, whilst in non 
obese subjects of both sexes, PLTP activity correlates positively with HDL (Murdoch et 
al. 2000; Cheung et al. 2002; Murdoch et al. 2002b). Infusion of apoA-I/PC discs into 
healthy male subjects causes an increase in plasma PLTP activity and an increase in small 
preβ-HDL (Kujiraoka et al. 2003). Furthermore, when an increase in HDL triglyceride 
content coincides with high plasma triglycerides, preβ-HDL formation is enhanced (Rye 
et al. 1998; Dullaart et al. 2001). Thus, high plasma triglycerides and PLTP activity levels 
possibly act together in promoting HDL conversion. Likewise, various studies have 
reported relationships between plasma PLTP activity, elevated plasma triglycerides and 
indexes of obesity (Dullaart et al. 1994b; Riemens et al. 1998b; Murdoch et al. 2000; 
Kaser et al. 2001b). In a clinical setting, plasma PLTP activity rises following a 24 h 
intravenous fat load and conversely, it decreases with diet-induced weight loss 
accompanied by reductions in abdominal subcutaneous fat in males and females 
(Riemens et al. 1999; Murdoch et al. 2003; Kaser et al. 2004). 
Plasma PLTP activity has also been associated with diabetes mellitus. Thus, in 
type 1 diabetes PLTP activity is increased and related to HDL subclass distribution 
(Colhoun et al. 2001; Colhoun et al. 2002). Furthermore, PLTP activity has been reported 
to be elevated in type 2 diabetic patients in association with high plasma triglycerides and 
obesity (Riemens et al. 1998; Riemens et al. 1998b). Likewise, plasma PLTP activity is 
not elevated in type 2 diabetic subjects with a relatively normal body mass index 
(Riemens et al. 1998b; Riemens et al. 1999). Attempts to decrease plasma FFA and 
triglycerides such as by insulin infusion and the administration of the nicotinic acid 
derivative, Acipimox, consequently decreases plasma PLTP activity, yet this decrease is 
blunted in obese type 2 diabetic patients (Riemens et al. 1998b; Riemens et al. 1999b; 
Dullaart et al. 2001b). Hence, high plasma PLTP activity in insulin-resistant states could, 
in part, be due to the diminished lowering by insulin. When comparing insulin-resistant 
with insulin-sensitive subjects without diabetes mellitus, a higher plasma PLTP activity is 
related to insulin resistance and appears associated with altered triglyceride metabolism 
(Riemens et al. 1998b; Jonkers et al. 2003). The suppressive effect of insulin on PLTP 
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activity has been demonstrated in vitro using HepG2 cells, and a suppression of PLTP by 
leptin; the adipocyte-derived hormone which also increases with body fat mass, has also 
been demonstrated (Kaser et al. 2001). 
Recently, plasma PLTP activity was found to be related to cardiovascular disease 
(CVD). Patients within the highest quintile of PLTP activity revealed a 1.9-fold increased 
risk for CVD compared to patients within the lowest quintile (Schlitt et al. 2003). The 
authors from this study concluded that PLTP activity is an independent predictive value 
for CVD. Whether this is the case or not, PLTP activity has at least been shown to 
increase when in conjunction with other independent risk factors for CVD such as 
cigarette smoking (Dullaart et al. 1994), excessive alcohol intake (Lagrost et al. 1996; 
Liinamaa et al. 1997), and the over consumption of diterpenes present in filter coffee (van 
Tol et al. 1997; De Roos et al. 2000). 
In atherosclerotic lesions, especially foam cell macrophages and SMCs, 
extracellular and cellular PLTP immunostaining is widespread suggesting that cellular 
cholesterol accumulation might increase PLTP expression (Desrumaux et al. 2003; 
O'Brien et al. 2003). However, the notion that PLTP may be a novel risk factor for CVD 
and a therapeutic target should be treated with extreme caution on the basis that PLTP 
may also function beneficially in certain tissues and organs. For example, PLTP mRNA 
is widely distributed throughout all regions of the central nervous system at levels 
comparable to other organs, and PLTP activity in cerebrospinal fluid (CSF) represents 15 
% of the plasma activity, showing that PLTP is synthesised in the brain. Interestingly, a 
significant increase in PLTP levels in brain tissue homogenates from patients with 
Alzheimer’s disease (AD) has been documented (Vuletic et al. 2003). Yet, when PLTP 
activity and mass are measured from the CSF of AD patients an overall reduction in 
PLTP levels compared to the control subjects is observed. PLTP in the CSF of patients 
with multiple sclerosis is also lower (Vuletic et al. 2005), and in the brains of patients 
with Down syndrome, there is a down-regulation of PLTP mRNA (Krapfenbauer et al. 
2001). This indicates that alterations in brain lipid metabolism and the pathogenesis of 
neurological diseases are closely linked. Human seminal plasma as well as human tear 
fluid also contain high levels of PLTP activity (Masson et al. 2003; Jauhiainen et al. 
2005). Notably, lung tissue displays the highest levels of PLTP compared to other tissues. 
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This suggests that PLTP may serve an important role in maintaining the normal function 
of this organ, such as in the transport of surfactant components, primarily phospholipid. 
PLTP gene is highly expressed in alveolar type II epithelial cells and is induced during 
hypoxia and in emphysema (Jiang et al. 1998). 
3.5. LOW ACTIVITY (LA) AND HIGH ACTIVITY (HA) PLTP 
One limiting factor in evaluating the physiological significance of PLTP has been the 
absence of a suitable method allowing for the quantification of PLTP concentration in 
biological samples from various human populations. In order to simultaneously measure 
PLTP mass and transfer activity from human samples, three separate groups developed 
specific ELISA methods (Desrumaux et al. 1999; Oka et al. 2000; Huuskonen et al. 
2000b). As each assay employed a different combination of polyclonal and/or 
monoclonal anti-PLTP antibodies, subsequent discrepancies in the correlations of PLTP 
mass and activity were observed. An explanation for the lack of association between 
PLTP mass and transfer activity is that two forms of PLTP exist in human plasma; one 
being catalytically active (HA-PLTP) and the other inactive (LA-PLTP) (Oka et al. 
2000). Adenovirus-mediated overexpression of human PLTP in mice also revealed the 
presence of two PLTP forms (Jaari et al. 2001). In human plasma, these two forms are 
associated with macromolecular complexes of different size so that the apparent size of 
LA-PLTP is 520 kDa and that of HA-PLTP is 160 kDa (Kärkkäinen et al. 2002). 
Following this, a partial characterisation of the two forms revealed that LA-PLTP is 
complexed with apoA-I while HA-PLTP co-purifies with apoE (Kärkkäinen et al. 2002). 
Using surface plasmon resonance analysis, PLTP was shown to bind apoA-I, apoE and 
also apoA-IV. Furthermore, the activation of LA-PLTP into an active form was achieved 
with proteoliposomes containing either apoE or apoA-IV, but not with those containing 
apoA-I (Jänis et al. 2005). Based on these findings, the authors have suggested a model in 
which nascent PLTP enters the circulation as a high specific activity form not associated 
with apoA-I. During or after the transfer of lipolytic surface remnants to HDL, PLTP is 
transferred to apoA-I-containing HDL particles and thereby rendered inactive. This 
hypothesis was, in part, fashioned from the calculated concentration of circulating LA-
PLTP which represented approximately 70 % of the total PLTP amount under 
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normolipidemic conditions (Oka et al. 2000). Soon after, Murdoch and co-workers 
questioned the above approximation of HA- and LA-PLTP distribution by demonstrating 
that differences in the reactivity of the antibodies toward HA- and LA-PLTP exist 
(Murdoch et al. 2002). For instance, they showed that the monoclonal antibody, against 
full-length recombinant PLTP, is more reactive to LA-PLTP and thereby overestimates 
its amount, consequently underestimating the amount of HA-PLTP. An explanation for 
the inability of the monoclonal antibody to quantitatively detect HA-PLTP is from a 
failure to form an immunocomplex due to the potential masking of specific PLTP 
epitopes and that the conformation of PLTP may differ when associated with 
macromolecular complexes of dissimilar size. It has therefore been deemed essential to 
improve the ELISA method so that both forms of PLTP can be measured precisely. 
4. PLTP AND ATHEROSCLEROSIS 
INSIGHTS FROM MOUSE MODELS 
The mouse has become a widely accepted model of human disease such as 
atherosclerosis, cardiovascular disease and hyperlipidemia (Paigen et al. 1994; Breslow 
1996). Studies relating to these cholesterol-related diseases have escalated since the 
advent of molecular techniques allowing for the creation of transgenic (Jaenisch 1988) 
and gene knockout mice (Capecchi 1989). Human PLTP transgenic mice, first created in 
1996 (Jiang et al. 1996), have resulted in a complicated phenotype. Transgenic mice that 
express moderate levels (~30 % increase) of human PLTP do not exhibit marked changes 
in lipoprotein metabolism, unless these mice are crossed into a human apoA-I 
background, and only after that, increases in α-HDL and preβ-HDL are observed (Albers 
et al. 1996; Jiang et al. 1996). An over-expression of huPLTP by adenovirus-mediated 
infection increases preβ-HDL levels, as well as decreases α-HDL and enhances the 
hepatic uptake of HDL-CE, thereby implying that the fractional catabolic rate of these 
particles is increased (Foger et al. 1997; Ehnholm et al. 1998). Transgenic mice 
expressing high, stable PLTP levels (2.5 - 4.5-fold increase in activity) display a 30 – 40 
% decrease in plasma HDL cholesterol and a concomitant rise in preβ-HDL formation, as 
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compared to wild type controls (van Haperen et al. 2000). Similar findings can also be 
seen from transient adenovirus-mediated over-expression of human PLTP (Jaari et al. 
2001). 
When intracellular cholesterol accumulation in macrophages became inhibited in 
PLTP transgenic mice it was concluded that PLTP behaves as an anti-atherogenic factor 
(van Haperen et al. 2000). However, further analysis of PLTP over-expression in mice 
heterozygous for the LDL-R revealed an increased potential for atherosclerosis due to a 
moderate elevation in VLDL secretion (1.5-fold) (Van Haperen et al. 2002). In order to 
study the contribution of CETP and PLTP in the metabolism of apoB-100-containing 
lipoproteins, mice transgenic for CETP and PLTP were created. These mice display a 
similar moderate 1.5-fold elevation in VLDL secretion (Lie J 2002). Conversely, when 
CETP and PLTP are over-expressed in the LDL-R heterozygous background (LDLR-
KO/huCETPtg/huPLTPtg), a strong PLTP dose-dependent decrease in VLDL and LDL 
cholesterol is observed and additionally, the activities of the anti-atherogenic enzymes 
PON-1 and PAF-AH are also PLTP-dose-dependently reduced (Lie et al. 2004). As HDL 
cholesterol is also diminished in these animals, the authors of this study concluded that 
these mice had an increased risk for atherosclerosis. 
Numerous insights into the role of plasma PLTP have also evolved from studies 
with PLTP deficient mice that were originally generated by homologous recombination in 
embryonic stem cells (Jiang et al. 1999). In PLTP-KO mice the in vivo phospholipid 
transfer from triglyceride-rich lipoproteins to HDL is completely abolished and when on 
a chow diet, a marked decrease in HDL phospholipid (60 %), cholesterol (65 %), and 
apoA-I (85 %) is observed. On a high-fat diet, the HDL levels in these mice are similarly 
decreased, but there is also an increase in VLDL and LDL phospholipids (210 %), free 
cholesterol (60 %) and cholesteryl ester (40 %), without changes in apoB-100 levels, thus 
suggesting an accumulation of surface components of triglyceride-rich lipoproteins (Jiang 
et al. 1999). In addition, the surface material deriving from the triglyceride-rich 
lipoproteins is a fraction enriched in lamellar structures composed of primarily apoA-IV 
(55 %) and apoE (25 %) and is enriched in phospholipid and free cholesterol (Qin et al. 
2000). The small HDL pool in these animals has been suggested to be the result of 
hypercatabolism of HDL protein and CE, an impairment that may possibly lead to the 
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condition of hypoalphalipoproteinemia. When the CETP transgene is expressed in the 
PLTP-KO background it is unable to compensate for the PLTP deficiency and causes a 
further lowering of plasma HDL concentrations (Kawano et al. 2000). Kawano and 
colleagues later showed that HL and SR-B1 play a major role in the clearance of free 
cholesterol and phospholipid surface remnants in the plasma of PLTP-deficient mice 
(Kawano et al. 2002). 
To address the involvement of PLTP in the turnover of apoB-100-containing 
lipoproteins and dyslipidemia, PLTP-KO mice were bred with different hyperlipidemic 
mouse strains. In this study, PLTP deficiency in apoB-100 transgenic and apoE-deficient 
backgrounds resulted in a reduced production and levels of apoB-100-containing 
lipoproteins, as well as reduced atherosclerosis. A diminished secretion of apoB-100 from 
the hepatocytes of these animals was also observed and could be corrected when PLTP 
was reintroduced by adenovirus (Jiang et al. 2001). The apparent defect in apoB-100 
secretion appeared to be not only a result of the lack of PLTP protein per se but also by 
the substantial reduction in the α-tocopherol content and elevated lipid peroxides in the 
livers of these mice, as compared to wild type. By replenishing the isolated primary 
hepatocytes with α-tocopherol, the hepatic oxidant tone was lowered which subsequently 
reduced the cellular ROS-dependent destruction of newly synthesised apoB-100 via a 
post-ER process. As the defect in apoB-100 secretion was fully restored by α-tocopherol 
alone, this new study bolstered the concept that PLTP inhibitors might be beneficial for 
increasing the α-tocopherol content also in plasma LDL (Jiang et al. 2005). Previous 
reports by the same authors demonstrated that the α-tocopherol content of VLDL and 
LDL was significantly increased in PLTP-KO mice (Jiang et al. 2002). Moreover, PLTP 
deficiency produced a dramatic delay in the generation of conjugated dienes in copper 
oxidised apoB-100-containing lipoproteins, and lower titres of autoantibodies to oxidised 
LDL. Thus, in mice, the bioavailability of α-tocopherol in atherogenic lipoproteins 
appears to be down-regulated by PLTP and PLTP deficiency could reduce their 
atherogenicity. When PLTP removes α-tocopherol from atherogenic lipoproteins, the 
propensity for atherosclerotic lesions to form is shown to increase (Yang et al. 2003). 
PLTP deficiency was also found to improve the anti-inflammatory properties of HDL as 
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well as to reduce the ability of LDL to induce monocyte chemotactic activity in human 
artery cell wall cocultures exposed to human LDL (Yan et al. 2004). 
Genetic mouse models have played a crucial role in elucidating the role of PLTP 
in lipoprotein metabolism and atherosclerosis whereby PLTP-transgenic and PLTP-KO 
mice have provided the first in vivo evidence for the vital role of PLTP in the 
maintenance of circulating HDL levels, in lipolytic phospholipid transfer from 
triglyceride-rich lipoproteins to HDL, and in the development of atherosclerosis. 
However, it still remains to be shown whether the same mechanisms operate in humans. 
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IV. AIMS OF THE STUDY 
1. To quantitatively determine the high-activity (HA) and low-activity (LA) PLTP 
forms in human plasma by modifying the ELISA method 
2. To correlate HA- and LA-PLTP with lipid and carbohydrate parameters in a 
normal Finnish population sample using the modified ELISA 
3. To characterise PLTP secreted by HepG2 cells, and to establish the association of 
PLTP with apolipoproteins in the secreted macromolecular complexes 
4. To investigate the effect of PLTP deficiency on hepatic lipid status, serum 
lipoprotein distribution, and on the biosynthesis of apoA-I in primary hepatocytes 
of PLTP-KO and control mice. 
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V. MATERIALS AND METHODS 
1. LIST OF PUBLISHED METHODS 
All of the methods that are listed in the table below have been used in this thesis and are 
sited according to the original publications in which they appear. Some essential methods 
that have contributed to this thesis as well as those not published will be explained in 
detail below. 
Method       Original Publication 
Purification of PLTP      I, II 
Detergent treatment of PLTP     I 
Calibration and optimization of PLTP ELISA  I 
Dextran-sulfate-CaCl2 precipitation of LA-PLTP  I 
ApoE genotyping      II 
Enzymatic lipid analysis     II, IV 
Statistical Analysis      I, II, IV 
Heparin-Sepharose Affinity Chromatography  I, III 
Size-Exclusion Chromatography    I, III, IV 
Immunoaffinity Chromatography    I, III 
SDS-PAGE       I, III,IV 
Western Blotting      I, III 
Enhanced Chemiluminescence detection   I, III 
Autoradiography      IV 
Lowry Protein Determination     I, II, III, IV 
PLTP activity assay      I, II, III, IV 
PLTP ELISA       I, II, III 
ApoA-I ELISA (human and mouse)    III, IV 
ApoB-100 ELISA      III 
ApoE ELISA       III  
Cell Culture       III 
Non-denaturing GGE      III 
Immunoprecipitation of PLTP    III 
Immunoprecipitation of apoA-I    IV  
Whole liver perfusion      IV 
Primary hepatocyte preparation and culture   IV 
Metabolic labeling      IV 
Lipid Extraction      IV 
Liquid chromatography/mass spectrometry   IV 
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2. PLTP EXPRESSION IN MAMMALIAN CELLS (UNPUBLISHED) 
The cDNA of full-length human PLTP lacking the stop codon was engineered by PCR 
and cloned into the pEGFP-N1 expression vector (BD Biosciences Clontech), linearised 
with ApaL1 (New England Biolabs) and transfected into the human hepatocellular liver 
carcinoma ATCC cell line, HepG2, using Fugene 6 transfection reagent (Roche). For the 
control cell lines, the pEGFP sequence was excised from pEGFP-N1 using Not1/EcoR1 
(New England Biolabs) and the remaining vector was transfected into cells. Single 
colonies expressing the PLTP-EGFP fusion protein or containing the empty vector were 
selected for the production of stable cell lines. As the pEGFP-N1 expression vector 
contains the neomycin gene, the selection antibiotic chosen was Geneticin (G-418 
sulphate; Life Technologies). 
The HepG2 stably transfected cell line was cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10 % fetal bovine serum (FBS) (Life 
Technologies), 100 IU/ml penicillin, 100 μg/ml streptomycin and 0.6 mg/ml Geneticin. 
The cells were seeded onto 6 cm dishes and incubated in serum-free culture medium for 
up to 48 h and the PLTP-EGFP fusion protein was characterized. The secreted PLTP-
EGFP protein was measured for activity and mass (methods described in publications I-
III) and EGFP fluorescence was measured with a Victor Spectrophotometer at 488 nm for 
excitation and 535 nm for emission. The accumulation of apolipoproteins secreted into 
the culture medium was measured by ELISA (method described in I, III). 
Live cell microscopy was employed for identifying the intracellular dynamics of 
the PLTP-EGFP fusion protein whereby 50 μg/ml of cycloheximide in serum-free 
medium was added to the cells and then followed for 4 h. Brefeldin A (Epicentre 
Technologies) was added at 5 μg/ml to the cells in serum-free medium and followed for 
30 min post-treatment at 10 min intervals. 
For immunofluorescence microscopy, the cells were fixed for 20 min at room 
temperature with 4 % paraformaldehyde, 250 mM Hepes, pH 7.4 and permeabilised for 5 
min with 0.1 % TX-100. The primary antibodies, diluted in 5 % FBS/PBS, were 
incubated for 30 min at 37 °C and the bound antibodies were detected with Alexa568-
conjugated goat anti-rabbit or anti-mouse IgG (Molecular probes). 
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VI. RESULTS AND DISCUSSION 
1. QUANTITATION OF HA- AND LA-PLTP BY ELISA 
Human plasma PLTP exists in two forms that are distinguished by their ability to transfer 
phospholipids and are thereby identified as high-activity (HA) and low-activity (LA) 
PLTP (Oka et al. 2000). Characterisation of each form demonstrates that they are 
associated with distinct macromolecular complexes of different size and of specific 
apolipoprotein composition (Kärkkäinen et al. 2002). In order to concurrently measure 
PLTP concentration with phospholipid transfer activity, three methods based on the 
ELISA principle have been established (Desrumaux et al. 1999; Oka et al. 2000; 
Huuskonen et al. 2000b). When HA- and LA-PLTP are separated from human plasma by 
chromatographic methods and the concentrations measured by ELISA, each form 
displays a dissimilar immunological reactivity with the antibodies used, and for this 
reason, is inaccurately detected (Murdoch et al. 2002). With accumulating evidence that 
each form distributes disproportionately in human plasma (Oka et al. 2000; Kärkkäinen et 
al. 2002), the biased overestimation of LA-PLTP and the subsequent underestimation of 
HA-PLTP has since called for a re-evaluation of the ELISA methods in use. In this thesis, 
we sought to improve the detection technique by modifying the conditions of the ELISA 
so that we could measure HA- and LA-PLTP precisely and thereby determine the true 
distribution of each form in normal human plasma. 
To improve the accuracy of PLTP mass detection, modification of the reported 
ELISA method required a denaturation step before antibody binding so that the 
detectability of the protein, especially that of HA-PLTP, would be improved. The 
denaturation capacity of five detergents in a sample pre-treatment step and whether they 
would improve the reactivity of human PLTP was evaluated. The detergents that were 
applied included anionic (SDS), cationic (CTAB), nonionic (OG and Tween 20), and 
zwitterionic (CHAPS) species. Each detergent was assayed at concentrations of 0.1 % 
and 0.5 %, and the critical micellar concentration differed for each detergent (I, Table 1). 
We found that from all of the detergents tested, 0.5 % SDS resulted in the largest increase 
in the immunoreactivity of human plasma PLTP (I, Table 1). Once SDS treatment was 
identified as the most suitable for plasma PLTP, we set out to re-calibrate the ELISA 
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using two primary standards: purified recombinant (r)-PLTP produced in the 
baculovirus/insect cell expression system, and PLTP purified from human plasma. We 
selected r-PLTP as the primary calibrator because i) the production and purification 
procedures are relatively straightforward and highly reproducible, and ii) no 
contamination bias from other plasma proteins is possible, which makes this recombinant 
protein a widely applicable calibration tool. Each calibrator was pre-treated with 0.5 % 
SDS and standard curves within the range of 25-100 ng PLTP/ml were obtained (I, Fig. 
2.). Each curve was linear throughout the entire concentration range and was suitable for 
the quantification of PLTP to as low as 0.0125 mg/l. When 70 % FBS was added to PLTP 
purified from human plasma, there was no matrix effect from the bovine serum since a 
total mass recovery of the primary calibrator was still fully obtainable. 
Having calibrated the ELISA, we used normolipidemic plasma from a healthy 
male volunteer to produce the secondary standard. When plasma was first treated with 
SDS and then diluted to cover a PLTP mass range of 25-200 ng PLTP/ml, a comparable 
slope to that of the primary standard curve was obtained (I, Fig. 3.). In order to determine 
the PLTP concentration in human serum, we assayed 80 serum samples from 
normolipidemic Finnish individuals and calculated the mean PLTP mass. The value 
obtained was 5.81 ± 1.33 mg/l (mean ± SD) and the mean phospholipid transfer activity 
was 5.84 ± 1.39 μmol/ml/h. This is in contrast to our previously reported mass value of 
15.6 ± 5.1 mg/l (Huuskonen et al. 2000b). An explanation for such a broad difference is 
that highly purified active plasma PLTP was used as the calibrator in the previous ELISA 
for PLTP and it obviously reacted poorly to the monoclonal capture antibody in the 
absence of a denaturing pre-treatment. This resulted in a low absorbance value for the 
calibrator, and correspondingly, to very high values for the serum samples. This was also 
the case for the active r-PLTP that was used in a similar ELISA method where a 
monoclonal capture antibody was applied (Oka et al. 2000). 
In order to study the reactivity of the two PLTP forms in human plasma with our 
modified ELISA, it was essential that we separate HA- and LA-PLTP first for analysis. 
This was achieved by utilising four separate methods, with three being chromatographic 
separations that have previously been reported (Kärkkäinen et al. 2002). From size-
exclusion, Heparin-Sepharose affinity and immunoaffinity chromatographies, we 
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successfully separated HA-PLTP from LA-PLTP. When we applied the HA-PLTP 
fraction, as separated by the three chromatographic methods, to the non-SDS ELISA, we 
detected only negligible PLTP mass. A significant increase in immunoreactivity for HA-
PLTP was only obtainable with SDS-denaturation and thereby enabled us to confirm, 
following all three methods, that in human plasma HA-PLTP represents approximately 
35 % of the total PLTP mass and LA-PLTP represents approximately 65 % (I, Fig. 4,5,6). 
Chromatographic methods used for separating HA- and LA-PLTP are somewhat 
laborious and too cumbersome for analysing PLTP distributions in a large clinical setting. 
Taking this into account, we introduced a fast new method for separating plasma HA- and 
LA-PLTP. This method applies dextran sulfate (DxSO4)-CaCl2 precipitation and involves 
the selective precipitation of LA-PLTP. We modified this method from previous studies 
that have used DxSO4-CaCl2 as a purification step for PLTP (Tu et al. 1993). In this 
approach, LA-PLTP is first precipitated from the sample, the concentration of HA-PLTP 
in the supernatant is measured and the value is then subtracted from the total plasma 
PLTP concentration to deduce a value for LA-PLTP. When applying this method to the 
sera of 80 randomly selected Finnish subjects, the mean concentration of HA-PLTP was 
1.87 ± 0.85 mg/l and LA-PLTP in the precipitate was 3.94 ± 1.4 mg/l. Hence, the mass 
distribution of HA-PLTP was calculated to be 32 % and that of LA-PLTP 68 %. These 
values are in accordance with the values obtained by the traditional chromatographic 
separations mentioned above. Furthermore, HA-PLTP mass correlated positively with 
serum PLTP activity, while LA-PLTP mass did not correlate at all (I, Fig. 7). The total 
serum PLTP concentration also correlated with total serum PLTP activity, albeit weakly, 
and this may be explained by the different apolipoprotein complexes that each form 
associates with and that the specific activity of HA-PLTP in the circulation may vary 
considerably during different metabolic stages. 
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2. CORRELATION OF HA-PLTP AND LA-PLTP WITH LIPID AND 
CARBOHYDRATE PARAMETERS IN A NORMAL FINNISH POPULATION 
SAMPLE 
In this thesis, we modified the PLTP ELISA method so that it would serve as a useful 
tool for measuring the two PLTP forms in human plasma (I). It would also enable us to 
address the mechanisms by which each form interacts with lipoproteins and how this 
influences the progression of atherosclerosis. We applied our modified ELISA to a 
Finnish population sub-sample (as part of a large Health 2000 Health Examination 
Survey) to analyse the distribution of serum HA- and LA-PLTP and to identify whether 
lipid and carbohydrate connections between the two PLTP forms exist. We measured the 
total PLTP concentration from the sera of 250 Finnish individuals and then determined 
the specific concentration of each PLTP form separated by DxSO4-CaCl2 precipitation. 
The total serum PLTP concentration was 6.56 ± 1.45 mg/l (mean ± SD), and 
approximately 46 % was in a catalytically active form; 3.00 ± 1.21 mg/l (range, 0.92-7.63 
mg/l). The mean concentration of LA-PLTP was 3.56 ± 1.14 mg/l (range, 1.20-8.43 
mg/l). These values are similar to what we obtained after we modified the ELISA (I). 
In order to study the correlation of PLTP transfer activity with the mass of HA- 
and LA-PLTP, we performed two separate radiometric assays on the serum samples: the 
exogenous assay (PLTPexo), measuring phospholipid transfer to exogenously added HDL 
(Damen et al. 1982), and the endogenous assay (PLTPendo), measuring phospholipid 
transfer to endogenous serum HDL (Lagrost et al. 1999). In both assays exogenously 
added radiolabeled PC-liposomes served as the phospholipid donor. The serum PLTPexo 
activity was 6.59 ± 1.66 μmol/ml/h, whereas the serum PLTPendo activity was 1.37 ± 0.29 
μmol/ml/h (II, Table 2). This difference in activity can be explained by the dependency of 
the PLTPendo assay on endogenous HDL levels which most likely reflect the activity of 
PLTP modulated by the composition of circulating lipoproteins. The two radiometric 
assays also resulted in different correlations to lipoprotein parameters and serum glucose 
(II, Table 4). PLTPendo activity correlated with total cholesterol, TG, and LDL-C, 
suggesting that lipoproteins other than HDL also significantly affect the outcome of the 
assay and therefore the endogenous PLTP activity level does not reflect the true amount 
of the active form of PLTP in serum. The exogenous assay, however, reveals more 
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directly the amount of active PLTP in serum. PLTPexo activity correlated with body mass 
index (BMI), waist-to-hip ratio (WHR) and VLDL, but not with LDL-C or HDL-C.  
As each of the two PLTP forms associates with different macromolecular 
complexes of varying apolipoprotein and lipid compositions, it is plausible that the 
phospholipid transfer activity of PLTP may be mediated by or be dependent on the 
apolipoprotein/lipid constituents of the macromolecular complexes. The observation that 
plasma HA-PLTP co-purifies with apoE and that apoE-containing liposomes are capable 
of activating LA-PLTP into a catalytically active form (Kärkkäinen et al. 2002; Jänis et 
al. 2005), prompted us to measure the apoE concentrations and isoform distributions in 
our sample population. The apoE allele frequencies were similar to those reported 
previously for Finns (Ehnholm et al. 1986). The ε2-carrying genotypes displayed the 
highest serum levels of apoE and had the highest serum PLTPendo activity. Both activity 
assays correlated weakly with total apoE, however, neither PLTPexo activity nor PLTP 
concentration correlated separately with the apoE isoforms. Therefore, the PLTPendo
activity levels that were detected in the ε2-carrying genotypes were most likely a 
reflection of the serum lipid/lipoprotein profile of the sample that had in some way 
affected the outcome of the endogenous assay. An explanation for the lack of any 
correlation between HA- or LA-PLTP concentration, the exogenous PLTP activity and 
the apoE isoforms may be due more or less to the normolipidemic sample population that 
was used and that different individual lipid/lipoprotein profiles were not distinguished 
from one another. A possibility also remains that the different apoE isoforms simply do 
not affect the PLTP parameters. 
In clinical approaches, PLTP has been linked to carbohydrate metabolism and 
indexes of obesity (Dullaart et al. 1994b; Riemens et al. 1998b; Murdoch et al. 2000). In 
addition, elevated PLTP activity has been associated with type 1 diabetes (Colhoun et al. 
2002), as well as with type 2 diabetic patients who have high plasma TG and are obese 
(Riemens et al. 1998b). We were interested in investigating whether any associations of 
insulin and/or glucose with HA- and LA-PLTP existed. PLTPexo activity correlated with 
glucose and with the index for insulin resistance (HOMA IR), supporting previous reports 
that high PLTP activity is related to insulin resistance and therefore high insulin levels 
(Jonkers et al. 2003). This data, in addition, suggests that PLTPexo activity could be 
48
elevated in metabolic syndrome. PLTPendo activity did not correlate with these parameters 
at all, whereas LA-PLTP did correlate with insulin while HA-PLTP did not (II, Table 4). 
Therefore, the distribution of the two PLTP forms appears to be influenced by lipid and 
glucose metabolism suggesting that, in the future, each form could serve as an 
independent marker for CVD risk evaluation. 
3. PLTP SECRETED BY HEPG2 CELLS RESEMBLES HA-PLTP IN HUMAN 
PLASMA 
One approach towards understanding the source of HA- and LA-PLTP in human plasma 
is to study the tissue- and cell-specific expression and secretion of nascently formed 
PLTP. Keeping in mind the expression pattern of human PLTP mRNA as well as the 
different size of each PLTP-expressing tissue, the liver is invariably one of the major 
sources of circulating PLTP, and is especially important when considering lipoprotein 
research. Therefore, we set out to characterise PLTP secreted from HepG2 cells, a human 
hepatoma cell line, and were interested in elucidating the interaction of PLTP with 
hepatic apolipoproteins. We chose HepG2 cells as the model system because they closely 
resemble lipid and lipoprotein metabolism in human liver; such as fatty acid uptake, lipid 
synthesis, apolipoprotein synthesis, and lipolytic enzyme and transfer protein synthesis 
(LCAT, CETP, and HL), along with apoB-100-lipoprotein assembly and secretion (Thrift 
et al. 1986; Arrol et al. 1991). 
We found that HepG2 cells secrete apoA-I, apoE and apoB-100 in appreciable 
amounts, and also PLTP displaying activity (0.30-0.35 μmol/ml/h at 48 h) (III, Fig. 1.). 
The concentration of PLTP was only measurable with our SDS-ELISA method as the 
mass was below immuno-detection levels with the previously reported ELISA (II), 
despite Western blot analysis indicating abundant PLTP amounts. At 48 h, the specific 
activity (an activity to mass ratio) of HepG2-derived PLTP was calculated to be 2.8-3.9 
μmol/μg PLTP protein/h. Surprisingly, this value is very close to the specific activity of 
HA-PLTP in human plasma (2.5-3.3 μmol/μg PLTP protein/h) (Kärkkäinen et al. 2002), 
suggesting that HepG2-derived PLTP resembles the high-activity form. We were not able 
to measure any LA-PLTP mass with the SDS-ELISA, nor could we separate any inactive 
PLTP from a Heparin-Sepharose affinity column, the method which is reported to 
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separate both PLTP forms (Kärkkäinen et al. 2002). HA-PLTP displays affinity for 
heparin and is retained on the column while LA-PLTP does not bind heparin and is 
therefore eluted immediately. 
Characterisation of the secreted PLTP entailed studying the size of nascent PLTP 
complexes secreted into the culture medium from HepG2 cells. Using non-denaturing 
gradient gel electrophoresis, we identified PLTP within the size range of 150-450 kDa 
and concluded that PLTP is secreted not as a monomer but instead, as part of a large 
complex. Additional properties of HepG2 PLTP were then established by using Heparin-
Sepharose affinity and size-exclusion chromatography. This data demonstrated that PLTP 
displays affinity for Heparin and that PLTP activity and mass co-elute with apoE in a 
position corresponding to the molecular mass of 160 kDa. All of these properties were 
akin to those of HA-PLTP isolated from human plasma, and as the derivation of HA- and 
LA-PLTP is suggested to involve an interaction with apolipoproteins, we decided to 
study the possible association of HepG2 PLTP with apoE. Polyclonal antibodies specific 
against human apoE were found to inhibit PLTP activity in a concentration-dependent 
manner, reaching 87 % inhibition at an IgG concentration of 0.5 mg/ml. Furthermore, 
PLTP quantitatively bound to an anti-apoE affinity column, and eluted at low pH with the 
portion of apoE that had also bound to the column. This suggests that high-activity 
HepG2 PLTP associates with apoE and this can be supported by recent data that plasma 
LA-PLTP is activated by apoE-containing liposomes (Jänis et al. 2005). Even though the 
present data suggests a functional role for apoE in PLTP activity, apoE deficient mice 
display normal levels of PLTP activity (M. Jauhiainen and K. Aalto-Setälä, unpublished 
observations). In addition, human tear fluid devoid of apoE contains only active PLTP 
eluting at the apparent molecular mass of 160 – 170 kDa in size-exclusion 
chromatography (Jauhiainen et al. 2005). A compensatory mechanism by other 
apolipoproteins such as apoA-IV, or possibly lipocalin in tear fluid, may be important for 
keeping the protein functionally active. This is supported by the recent finding that also 
apoA-IV proteoliposomes activate LA-PLTP (Jänis et al. 2005). Finally, the present study 
demonstrates that HepG2 cells are a relevant model system to study the high-activity 
form of human plasma PLTP secreted by hepatocytes. 
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4. STABLE EXPRESSION OF A PLTP-EGFP FUSION PROTEIN IN HEPG2  
CELLS 
In order to study the intracellular localisation and possible function of PLTP, we utilised 
the human hepatoma cell line, HepG2, to develop a line that constitutively over-expresses 
a fluorescently tagged PLTP-EGFP fusion protein. In accordance with the observation 
that PLTP is translocated into the ER lumen and secreted by HepG2 cells (III), the PLTP-
EGFP fusion protein was found to be localised within the secretory pathway. PLTP-
EGFP fluorescence was dominant in the Golgi apparatus and the fusion protein was also 
detected in reticular ER compartments [Fig 4].  
A co-localisation of PLTP-EGFP with the Golgi marker antibodies, cis-Golgi marker 
(GM)-130, ER Golgi Intermediate Compartment (ERGIC)-53, and Trans Golgi Network 
(TGN)-46, was demonstrated, hence confirming a localisation of PLTP-EGFP to the 
Golgi complex [Fig 5]. When the Golgi stack was dissociated with the fungal toxin 
Brefeldin A, PLTP-EGFP staining was dispersed to a more ER-like pattern, thus further 
confirming localisation of the protein within Golgi compartments [Fig 4]. When the more 
peripheral parts of the cells were studied using a higher photomultiplier gain, co-
localisation with the ER marker Protein Disulphide Isomerase (PDI) was also observed 
[Fig. 5]. When protein synthesis was inhibited with 50 μg/ml cycloheximide, PLTP-
EGFP was chased out from the secretory pathway within 3 h [Fig 6], an observation well 
0 min 15 min
Fig. 4. PLTP-EGFP HepG2 cells in 10 % FBS +/- Brefeldin A
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within the range of secretion rates determined for several other plasma proteins (Ledford 
et al. 1983; Lodish et al. 1983; Fries et al. 1984). 
HepG2 PLTP-EGFP
TGN-46
GM-130
HepG2 PLTP-EGFP
Overlay
Overlay
ERGIC-53
PDI
HepG2 PLTP-EGFP
HepG2 PLTP-EGFP Overlay
Overlay
Fig. 5. Immunofluorescence image of PLTP-EGFP and different Golgi markers 
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Given that PLTP-EGFP was detected within the secretory pathway, the next step was to 
measure PLTP-EGFP secreted into the culture medium. This was performed by 
incubating the cells in serum-depleted medium for up to 48 h, collecting the medium and 
radiometrically assaying the phospholipid transfer activity (Damen et al. 1982; Jauhiainen 
et al. 1993). PLTP mass was also measured using the SDS-ELISA (I), and fluorescence 
was measured with a Victor Spectrophotometer at 488 nm for excitation and 535 nm for 
emission. From these measurements, the secreted PLTP-EGFP fusion protein displayed a 
low specific activity (SA = 0.07 μmol/μg per h) [Fig 7.1]. In contrast, the mock 
transfected cell line secreted endogenous PLTP which displayed a high specific activity 
(SA = 1.7 μmol/μg per h) [Fig 7.2]. Analysis of EGFP fluorescence in the medium 
revealed a time-dependent increase of fluorescence by the PLTP-EGFP cells that greatly 
exceeded background levels observed in the medium of mock-transfected cells. The size 
and presence of the proteins that were secreted into the culture medium and within the 
cells were confirmed by Western blotting with anti-PLTP full-length and anti-GFP 
peptide antibodies. The bands that were resolved from the cells were the PLTP-EGFP 
fusion protein representing the intracellular ER and cis-Golgi PLTP forms 
(approximately 92 kDa) [Fig 8.1], and in the culture medium representing the fully 
glycosylated PLTP-EGFP form (approximately 110 kDa) [Fig 8.2]. 
0h 1h 3h
Fig. 6. PLTP-EGFP HepG2 cells + 50μg/ml cycloheximide
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Fig. 7. Characterization of the secreted PLTP-EGFP fusion protein. 
1) PLTP-EGFP secreted from HepG2 stable cell line. 2) Endogenous 
PLTP secreted from the mock transfected cell line. 3) Fluorescence 
measured from mock transfected and PLTP-EGFP expressing cells.
54
Fig. 8. Western blot of PLTP-EGFP from stable-transfected HepG2 cells. 
1)  Anti-GFP antibody detecting the fusion proteins: 92 kDa band 
represents intracellular ER and cis-Golgi PLTP, 110 kDa form represents 
the fully glycosylated form. 2) Anti-PLTP mAb59 monoclonal antibody 
detecting the fusion protein secreted into the culture medium with one 
110 kDa band .
92 92
1. 2.
12 24 48 h
12 24 48 h
92 kDa
110 110 kDa
When studying the effect of PLTP-EGFP over-expression on the secretion of certain 
apolipoproteins, we found that the accumulation of apoA-I into the culture medium from 
the stable cell line was significantly diminished compared to the mock-transfected cells 
[Fig 9.]. Even though PLTP-EGFP is secreted from the stable-transfected cells, the low-
specific activity suggests that the fusion protein is defective and may interfere with the 
secretion of apoA-I.  This suggests that active PLTP could be involved in the secretion of 
apoA-I or in its stabilization in the culture medium and may therefore play a role in the 
early steps of HDL biosynthesis. Evidence from ABCA1 studies suggest a role for PLTP 
in cholesterol efflux at the extracellular face of plasma membranes whereby PLTP may 
interact directly with either apoA-I or ABCA1 or both during cholesterol efflux 
(Wolfbauer et al. 1999; Oram et al. 2003). It is also possible that PLTP facilitates the 
early phospholipidation of apoA-I within the secretory pathway post-synthesis in the 
Golgi region (Mendez et al. 1996; Bhat et al. 2004), or is involved in the recycling of 
ABCA1 and apoA-I through endocytic compartments (Neufeld et al. 2004). Furthermore, 
the possibility that PLTP might be directly involved in the phospholipidation of apoA-I or 
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in its secretion from the Golgi complex was raised by the finding that PLTP-EGFP and 
the endogenous apoA-I synthesised in the HepG2 stable cells extensively co-localised in 
the Golgi complex [Fig 10]. In order to investigate these hypotheses using a more 
physiological setting, we decided to study the role of PLTP in the biosynthesis of apoA-I 
from primary hepatocytes by applying an available PLTP gene knock-out mouse model. 
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Fig. 9. Accumulation of apoA-I in the culture medium from 
PLTP-EGFP HepG2 cells
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5. LIPOPROTEIN AND LIPID LEVELS IN PLTP-KO MICE 
PLTP deficiency in mice has been reported to result in markedly decreased HDL 
phospholipid (60 %), cholesterol (65 %), and apoA-I (85 %) levels (Jiang et al. 1999). 
PLTP deficiency has also been implicated in decreased secretion and levels of apoB-100-
containing lipoproteins as demonstrated by crossing the PLTP deficiency trait into apoE-
deficient and apoB-100 transgenic backgrounds (Jiang et al. 2001). Increasing evidence 
that PLTP may play a role in hepatic lipoprotein biosynthesis is also demonstrated from 
findings that human PLTP is associated with apolipoproteins in vitro (Pussinen et al. 
1998; Kärkkäinen et al. 2002)(III), and in vivo (Barlage et al. 2001). In order to 
investigate the impact of PLTP deficiency on lipoprotein biosynthesis, we measured 
mouse hepatic tissue lipid status, the serum lipoprotein profiles, and apolipoprotein A-I 
secretion from primary hepatocytes in culture. The animals we used were female, they 
were grouped according to age; 6, 12 and 18 weeks, and were produced in a C57Bl/6 
background (wild type, WT; PLTP-knock out, PLTP-KO). 
 With data on serum and hepatic lipid levels in PLTP-KO mice at different age 
groups being limited, we designed a study that would enable us to identify lipid level 
changes, that if present, would occur with age. Comparing each age group, all animals at 
the onset of sample collection were of similar body mass, liver mass, and displayed 
similar liver to body mass ratios (IV, Table1). As expected, PLTP-KO mice at all ages 
displayed decreased serum total cholesterol and apoA-I levels when compared to the WT 
R34 anti-apoA-IHepG2 PLTP-EGFP Overlay
Fig. 10. Immunofluorescence image of PLTP-EGFP co-localising with apoA-I in the Golgi
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controls, and at 6 weeks of age serum choline phospholipids were also reduced in the 
PLTP-KO mice (IV, Table 1, 2). We also measured serum TG and FFAs and found no 
significant differences between the groups. To analyse serum lipoprotein profiles we 
pooled serum from four mice within each group at the age of 12 and 18 weeks. 
Lipoproteins were separated by size-exclusion chromatography and the elution profile for 
the PLTP-KO mice revealed a TG, choline phospholipid (PL) and cholesterol peak 
distribution predominantly within fractions corresponding to the elution position of 
VLDL (IV, Fig 1). In the 12 week old PLTP-KO sera, TG levels in the position of VLDL 
were elevated in comparison to WT (IV, Fig 1A, B).  
The elevated TG in serum VLDL fractions may be connected with increased liver 
TG that was also observed in the PLTP-KO animals, an elevation of up to 30 % at 6 and 
12 weeks of age. There were no differences in hepatic lipid peroxidation levels and since 
we found no increase in serum FFA, the most obvious cause for liver TG accumulation, 
the molecular mechanisms leading to increased TG still remain unclear. It is possible that 
the increased levels of hepatic TG are due to intracellular regulatory changes in TG 
synthesis (Farese et al. 2000), FA β-oxidation (Grefhorst et al. 2005), or alterations in 
hepatic glucose metabolism (Bandsma et al. 2001; McDevitt et al. 2001). The analysis of 
hepatic lipids also revealed an elevation in PL and cholesterol in the PLTP-KO mice, 
while bile acid synthesis appeared normal, if not elevated (IV, Table 2, 3). The general 
view is that cholesterol carried in HDL is the major precursor for hepatic bile acid 
synthesis (Botham et al. 1995). This suggests that the lack of PLTP activity in these mice, 
resulting in diminished circulating HDL levels, may lead to hepatic uptake of plasma 
LDL cholesterol and/or subsequent alterations in cellular cholesterol and PL homeostasis. 
Increased cholesterol biosynthesis would be a likely pathway to investigate for future 
studies. 
As recent reports suggest that of all newly synthesised apoA-I a substantial 
portion is lipidated intracellularly (Chisholm et al. 2002; Zheng et al. 2005), and with 
PLTP-EGFP in HepG2 cells co-localising with apoA-I in the Golgi compartment, we 
thought it would be interesting to study the involvement of PLTP in the secretion of 
apoA-I or nascent HDL by the liver. We isolated primary hepatocytes from PLTP-KO 
and WT mice (8-12 weeks of age) by whole liver collagenase perfusion and examined the 
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synthesis and secretion of apoA-I from these cells. The accumulation of apoA-I into 
serum-free culture medium up to 24 h, as measured by ELISA, revealed that at the latest 
time points the PLTP-KO hepatocyte culture medium contained 66 % lower apoA-I 
levels when compared to that of the WT hepatocytes (IV, Fig 2). This indicated to us that 
either (i) there was a secretion defect of apoA-I in the hepatocytes, or (ii) increased 
proteolytic degradation occurring in the cells or culture media. To address the question of 
synthesis and secretion, we carried out metabolic labeling of newly synthesised apoA-I, 
with or without a 24 h pre-incubation in serum-free medium, followed by a 3 h chase 
period. This revealed that the synthesis of apoA-I in both cell types is similar (IV, Fig 3). 
The 24 h pre-incubation in serum-free medium was designed to eliminate any 
possibilities that the apoA-I defect would arise after a delayed response by the PLTP-KO 
cells to reduce their synthesis of apoA-I following serum depletion. Having established 
that PLTP deficiency incurs no impairment on the biosynthesis or secretion of apoA-I, we 
considered that an instability of the protein would be the likely cause for the progressive 
reduction in the accumulation of the protein over time. 
Degradation of exogenously added lipid-free apoA-I by PLTP-KO and WT 
hepatocytes was detected upon a 24 h incubation in conditioned medium from both cell 
types so that the trichloroacetic acid (TCA) precipitable non-degraded fraction 
represented 42 ± 0.5 % (SD) from PLTP-KO and 50 ± 5.7 % from WT media. When 
exogenous apoA-I was incubated with the cells, degradation from the PLTP-KO cells was 
35 ± 5.0 % and from WT, 41 ± 11 %; values slightly higher than from conditioned 
medium alone, but comparable for both cell types. This demonstrates that PLTP-KO and 
WT cells degrade lipid-free apoA-I to a similar extent. Therefore, with degradation being 
similar in both cell types, we consider it most likely that the increased instability of the 
apoA-I produced by the PLTP-KO cells is caused by a difference in protease 
susceptibility, probably due to a difference in lipidation. 
To address the likelihood that apoA-I secreted from PLTP-KO cells is lipidated 
differently to WT apoA-I, we employed liquid chromatography/mass spectrometry 
(LC/MS). We found that apoA-I from the PLTP-KO cells contained a lower total amount 
of PL (32 % decrease; IV, Fig 4A), and the PC/SM ratio was also significantly reduced 
(IV, Fig 4B). Detailed analysis of the apoA-I PL species composition for each PL class 
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revealed a substantially different composition in the PLTP-KO apoA-I compared to WT 
(IV, Fig 5A). This difference was also evident in the PLTP-KO cells (IV, Fig 5B-F), 
whereby a relative decrease in the long-chain arachidonic acid (20:4)-containing species 
was evident and seemed to be compensated for by a relative increase in medium-chain 
FA-containing PL species. In addition, a relative increase of certain docosahexaenoic acid 
(22:6)-containing species in the PLTP-KO cells was observed. These differences in PL 
molecular species composition of the PLTP-KO hepatocytes and PLTP-KO apoA-I were 
almost identical, whereas the PL species of the WT cells and apoA-I produced by them 
showed distinct differences (IV, Fig 5A,B). This suggests that in PLTP deficiency, newly 
synthesised apoA-I is phospholipidated differently either within the secretory pathway or 
at the plasma membrane, which leads to destabilization and ultimately impaired 
accumulation of the protein into the culture medium. A suggested role for PLTP in the 
partial lipidation of newly synthesised apoA-I during nascent HDL formation from the 
liver is now presented as an essential process for the effective stabilization of the protein. 
Therefore, an altered hepatic lipid status and impaired biosynthesis of nascent HDL in the 
PLTP-KO mice reveals a role for PLTP in hepatic lipid homeostasis. 
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VII. SUMMARY AND CONCLUSIONS 
This doctoral thesis consists of a number of studies in which different aspects of PLTP 
research are tackled so that the role of how PLTP influences hepatic lipoprotein 
metabolism in the context of dyslipidemias and atherosclerotic disease progression can be 
further understood. The approaches used in this thesis stem from studies performed in 
human serum, in cellular model systems, and in genetically modified mice that display 
the PLTP deficiency trait. The objectives were (i) to develop a new and applicable 
laboratory assay for measuring the two forms of PLTP, (ii) to apply this assay in a 
clinical setting, and (iii) to study the characteristics and likely role of PLTP in lipoprotein 
and lipid metabolism in the liver.  
 The first part of this thesis aimed at developing an accurate ELISA method that 
would quantitatively measure the HA and LA forms of human plasma PLTP. By applying 
a simple, yet effective pre-treatment of the samples, we discovered that the detectability 
of HA-PLTP dramatically improved via exposure of epitopes that were otherwise 
concealed for antibody detection. Calibration of the new ELISA, that would be applicable 
to most laboratories, as well as the introduction of a fast and effective method (DxSO4-
CaCl2 precipitation) to separate HA-PLTP from LA-PLTP, provides new tools that have 
previously been unavailable. This innovative approach for PLTP analysis has since 
allowed for accurate and comparable measurements of total PLTP protein concentration 
in plasma or serum samples and for determining the distribution of PLTP between the 
LA-PLTP and HA-PLTP forms. In doing so, this methodology will be useful for 
establishing the relationship that PLTP mass and activity have with associated 
lipoproteins, plasma factors, and lipid metabolism in general. 
 This leads to the second part of this thesis in which the methodology for PLTP 
mass determination was applied to a random Finnish population sample (n = 250). The 
association of PLTP activity and the concentration of both forms with lipid and 
carbohydrate parameters were investigated. Of the total serum PLTP concentration, 
approximately 46 % was in a catalytically active form and this HA-PLTP form correlated 
positively with serum PLTPexo activity, HDL cholesterol and apoA-I. The role for PLTP 
in PL transfer activity and in HDL conversion has been well established, and with the 
positive associations of HA-PLTP with HDL parameters identified in this study, we now 
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await large, prospective studies on PLTP to assess whether concentration, activity, or 
both combined can be used as independent markers for cardiovascular risk evaluation. 
 When the importance of HA- and LA-PLTP in human plasma in disease 
progression is better understood, the source of each form and the properties of each must 
be established. As most studies on PLTP have been performed in human plasma, we 
decided to direct our studies to the tissue- and cell-specific expression and secretion of 
nascently formed PLTP. We set out to characterise PLTP secreted from HepG2 cells, a 
human hepatoma cell line, and were interested in elucidating the interaction of PLTP with 
hepatic apolipoproteins. We established that PLTP secreted from HepG2 cells closely 
resembles the high-activity PLTP form isolated from human plasma, and in addition, 
associates with apoE. ApoE is a powerful regulator of lipoprotein metabolism in human 
serum and has recently been shown to activate human plasma LA-PLTP (Jänis et al. 
2005). Therefore, this study presents the HepG2 cell model as a tool (i) for studying the 
mechanisms by which active PLTP becomes converted into the low-activity form 
associated with apoA-I, and (ii) for studying the intracellular function of newly 
synthesised PLTP. In this thesis, we also utilized HepG2 cells for developing a stable cell 
line that would constitutively over-express a PLTP-EGFP fusion protein. This fusion 
protein was efficiently secreted and within the secretory pathway it was found to 
concentrate in the Golgi compartment, to co-localize with apoA-I, and also to inhibit the 
accumulation of apoA-I in the culture medium. Consequently, these cells provided us 
with the clue that PLTP could serve an intracellular role in the biosynthesis and/or 
stabilization of apoA-I and may be a regulator of HDL formation. 
The final study of this thesis utilizes the PLTP gene knockout mouse model to 
investigate the hypothesis that PLTP is required for the biosynthesis of apoA-I and may 
be an important regulator of hepatic lipid metabolism. In the situation of PLTP 
deficiency, we confirmed previous findings that plasma HDL cholesterol and apoA-I in 
these mice are severely reduced and that the cholesterol distribution is mostly in the 
fractions eluting in the VLDL and LDL region, also found to contain elevated TG. 
Furthermore, the hepatic lipid composition was drastically altered in PLTP-KO animals 
with cholesterol and choline phospholipid being elevated in each age group, along with 
increased TG in the younger mice. We concluded that without any increases in lipid 
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peroxidation or impairment in bile acid secretion, the observations would most likely be 
attributed to cellular alterations in cholesterol biosynthesis or increased uptake of apoB-
100-containing lipoproteins as a result of a decreased amount of HDL cholesterol 
available for hepatic uptake. We also studied the effect of PLTP deficiency on HDL 
biosynthesis in the primary hepatocyte cultures of these mice and found that apoA-I is 
phospholipidated differently to WT, which presumably affects the stability of the protein 
in the culture medium upon secretion. Such lipid-related outcomes of PLTP deficiency in 
mice demand further investigation and illustrate the magnitude of consequences that 
manipulation of HDL populations by PLTP inactivation would cause on lipid metabolism 
as a whole. 
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